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ABSTRACT 
TRICIA M WRIGHT: Identification and Characterization of Ror2 as a Tumor Cancer 
Cell Specific Kinase in Renal Cell Carcinoma 
(Under the direction of W. Kimryn Rathmell) 
 
With the recent advent of molecularly targeted therapy, the potential for novel 
treatment options for carcinomas has been brought to the forefront.  However, few 
tumor cell-specific targets exist for many cancers.  Our goal was to identify and 
characterize cell specific kinases for the difficult to treat epithelial cancer renal cell 
carcinoma (RCC).  Using a phospho-specific receptor tyrosine kinase screen, we 
identified Ror2, a developmentally regulated orphan receptor kinase, to be 
overexpressed in RCC tumors and cell lines.  Ror2 is normally expressed in the 
heart, brain, kidney and lungs of developing mice and has also been implicated in 
the Wnt/β-catenin signaling pathway.  Using archival RCC tumor specimens, we 
show that Ror2 was coordinately overexpressed with genes involved at the 
extracellular matrix (ECM), including MMP2.  Consequently, when Ror2 was 
suppressed in cell lines, MMP2 expression was also suppressed, suggesting Ror2 
may play a role in directing MMP2 expression.  Ror2 suppression also supported 
cellular migration, without affecting doubling time or viability.  Additionally, inhibition 
of Ror2 limited RCC growth in soft agar, a surrogate for invasive growth potential 
and anchorage independence, and produced fewer tumors in vivo in xenografts.   
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Since the discovery of Ror2 in RCC, Ror2 has since been implicated in 
several other cancers, where it is associated with invasive tumor characteristics.  
However, the regulatory or mechanistic events contributing to increased Ror2 
expression had yet to be defined.  We sought to place Ror2 in the most studied 
pathway in RCC, the inactivation of the tumor suppressor von Hippel-Lindau, VHL, 
leading to hypoxia induced factor (HIF)-1α and 2α dysregulation.  We found that 
Ror2 expression was associated with pVHL loss and that VHL somatic mutations 
tightly coordinated with HIF-2α stabilization.  Knockdown and rescue analysis of HIF 
expression suggests that Ror2 is dependent on the pathologic stabilization of both 
HIF1 and HIF2.  However, induction of HIF by physiological hypoxia did not affect 
Ror2, suggesting a unique regulation of Ror2 dependent on non-physiologic HIF 
activation.  This study identifies a novel putative kinase involved in key aspects of 
RCC tumorigenesis and also offers insight into how Ror2 is deregulated in RCC with 
potential application to other cancers.  
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CHAPTER 1 
 
INTRODUCTION 
 
 
 
 
 
Pathogenesis of Renal Cell Carcinoma 
Sporadic renal cell carcinoma (RCC), one of the top 10 cancers diagnosed in 
the US per year (1), is the most common kidney malignancy.  RCC, a notoriously 
hard to treat solid tumor malignancy, has minimal sensitivity to traditional 
chemotherapy and immune system modulation, the treatment of choice for the past 
20 years.  This devastating disease is diagnosed in over 40,000 new cases per year 
(1), with over half of those diagnosed developing metastatic disease.  Alarmingly, 
the incidence of RCC is rising steadily at rate of 3% per year with men twice as likely 
as women to present with RCC.  While the causes of renal cell carcinoma are 
unknown, certain risk factors including smoking and obesity are recognized as 
potential inducers of RCC, with those who smoke being twice as likely to acquire the 
disease.  Additionally, exposures to certain occupational toxicants such as asbestos, 
gasoline and trichloroethylene have all been recognized as possible factors 
escalating the possibility of developing RCC. 
Several different pathological types of RCC have been identified including 
papillary and chromophobe.  However, it is clear cell histology of RCC that makes up 
approximately two-thirds of patients with this disease.  Pathologically, clear cell RCC 
tumors have a highly glycolytic, vascular phenotype in which they accumulate lipids 
and glycogens in the cytoplasm.   As a result, these tumor cells present with a clear 
cytoplasm and nuclei as compared to the two other histological subtypes, papillary 
and chromophobe (Figure 1.1) when stained with H&E.  These distinct 
morphological characteristics give these tumors the classification of “clear cell”.  This 
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body of work will focus specifically on the clear cell pathological subtype of RCC 
(either listed as ccRCC or simply RCC).   
Clear cell RCC occurs sporadically and as part of the familial von Hippel-
Lindau (VHL) disease.  Biallelic mutations and functional inactivation of the VHL 
tumor suppressor protein (pVHL) have been identified as major contributory factors 
to both forms of the disease (3-6).  The tumor suppressor gene VHL is mutated in 
over 70% of clear cell RCC histologies leading to overexpression of key growth 
factors, including platelet-derived growth factor (PDGF) and vascular endothelial 
growth factor (VEGF), among many others (7, 8).  
The most current and effective therapies for renal cell carcinoma involve the 
use of kinase-specific inhibitors targeted against receptor tyrosine kinases (RTK) 
and ligands specific to angiogenesis signaling.  However, though these agents have 
shown promise with a short extension in overall lifespan compared to the control 
agents, they have yet to be fully optimized.  Currently, there are no reported cancer 
cell specific kinases expressed on RCC identified as targets for tumor cell directed 
therapy.  Though there is an abundance of RTK inhibitors including sorafenib and 
sunitinib that have shown promise in RCC treatment (9-13), they have yet to be fully 
optimized providing a rationale for finding cell intrinsic kinase targets in RCC.  
Finding these kinase targets will in turn provide a rational pharmaceutical target for 
future therapeutic development.     
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Molecular Biology of RCC 
The von Hippel-Lindau tumor suppressor gene encodes a 213 amino acid 
(aa) protein, pVHL, whose mainly recognized role is to regulate the cellular response 
to changes in oxygen.  The most well-documented function of the pVHL protein, 
which encompasses an α and β subunit,  is to act as the substrate recognition 
component of an E3 ubiquitin ligase complex that includes Elongin C, Elongin B, 
Cullin 2, and ring box protein 1 (Rbx1 or Roc1) (14-17).  The majority of clear cell 
RCC tumors are mutated for VHL leading to overexpression of hypoxia inducible 
transcription factors (HIF) including, but not limited to, VEGF and PDGF (18, 19).   
Under normal oxygen conditions and when pVHL is functional, the HIFα 
subunits (HIF1, HIF2) are hydroxylated on specific prolyl residues by prolyl 
hydroxylases (known as PHD or Egln) in the oxygen dependent degradation (ODD) 
domain (20-22).  The hydroxylated HIFα subunit is polyubiquitinated after being 
recognized by and recruited to the pVHL E3 ubiquitin ligase complex and then 
degraded by the proteasome (Figure 1.2A).  Under low oxygen conditions (Figure 
1.2B) or when VHL is mutated (Figure 1.2C) leading to a pseudohypoxic state, pVHL 
is unable to bind either HIFα subunit.  This inability to bind leads to accumulation of 
the HIFα subunits which in turn forms a heterodimeric transcriptional complex with 
HIF1-β (also known as (ARNT) aryl hydrocarbon receptor nuclear translocator) that 
is translocated to the nucleus.  This nuclear translocation leads to transcriptional 
activation via binding to conserved hypoxia response elements (HREs) and 
induction of hypoxia inducible target genes including VEGF, PDGF, glucose 
 5
transporter 1 (Glut1), prolyl hydroxylase family member Egln3 (also known as PHD3) 
and many other hypoxia factors (7) (Figure 1.2B, C).  
Protein stabilization of the HIF subunits can also be achieved independently 
of VHL mutations through activation of the mammalian target of rapamycin (mTOR) 
pathway, another key regulator of tumor cell responses.  mTOR is an intracellular 
serine/threonine kinase activated upstream of HIF and is part of the PI3K/Akt/mTOR 
signaling pathway.  There are two distinct macromolecular complexes of mTOR, 
mTOR complex 1 (mTORC1), which is susceptible to rapamycin and contains raptor 
and mTORC2, which is rapamycin insensitive and contains rictor.  Mutations 
disrupting mTORC1’s proximal negative regulators, the tuberous sclerosis complex 
family members (TSC) 1 and 2 which is characterized by PTEN loss, predisposes to 
RCC development (23, 24).  When the mTORC1 complex is mutated or otherwise 
inhibited, the PI3K/Akt pathway is activated leading to mTORC1-dependent protein 
stabilization (at the level of translational initiation) causing upregulation of the HIF 
subunits (25).  Though more is known about the role of mTORC1, mTORC2’s role in 
RCC is not as well-defined.  However there is a difference in the mTOR subunits 
and the subsequent dependence of the HIF subunits.  In fact, HIF-1α is dependent 
on both mTORC1 and mTORC2 whereas HIF-2α is dependent only on mTORC2 
(25).  Further, mTORC2 does not respond to rapamycin but appears to be generally 
associated with the cytoskeleton. 
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Figure 1.2: The control of O2 regulated genes.  
A. With normal O2 levels and when pVHL is functional, VHL recognizes (specifically, the β 
subunit) and binds the hydroxylated HIFα subunit.  The HIFα subunit is polyubiquitinated 
and subjected to proteasome mediated degradation.   
B. Under low O2 levels or if C. VHL is inactivated, VHL is no longer able to bind to the 
hydrolyxated HIFα subunit leading to an increase in binds to HIFα subunits.  (mTOR 
activation also causes upregulation of the HIFα subunits, though this activation is 
independent of VHL inactivation). HIFβ then heterodimerizes with the HIFα subunit, is 
stabilized and translocates to the nucleus.  The stabilized HIF subunit then leads to the 
transcriptional activation of many HIF target genes. Figure adapted from Rathmell WK, 
Wright TM & Rini B Expert Rev Anticancer Ther 2005 (19). 
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HIFα independent functions of pVHL 
Though VHL is widely known to function in response to cellular oxygen changes, it 
also has other roles within the cell (Figure 1.3).  VHL has also been shown to have a 
role in the regulation of apoptosis, maintenance of primary cilia (26, 27) and 
extracellular matrix remodeling (28, 29).   
 
Apoptotic regulation.  RCC is notoriously resistant to cytotoxic treatments and 
this may be partially due to inactivation of apoptotic pathways or activation of 
prosurvival pathways.  Emerging evidence suggests that pVHL plays a pivotal role in 
apoptotic regulation.  pVHL has been shown to bind to, and inhibit, atypical protein 
kinase C (aPKC) (30, 31).  aPKC has been implicated in cellular processes such as 
cellular proliferation, cellular survival, and in establishing and maintaining cellular 
polarity including cell-cell junctional maintenance.   VHL expression and inactivation 
of aPKC leads to increased JunB expression which in turn antagonizes c-jun 
mediated neuronal apoptosis.   
Additionally, other HIF-independent VHL-mediated factors of apoptosis have 
been identified including nuclear factor κB (NFκB) and p53.  Kidney cancers have 
increased expression of NFκB (32), normally associated with survival and pVHL loss 
is shown to activate NFκB expression (33).  VHL serves as a liaison by binding and 
phosphorylating the NFκB antagonist Card9 along with casein kinase 2 (CK2) 
leading to decreased NFκB activity.  VHL also forms a complex with p53 along with 
ATM and p300, both of which promote p53 stabilization and activation (34, 35).  
When under genotoxic stress, there is interaction of p300 and p53 leading to p53 
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acetylation and increased expression in concert with p53 mediated cell cycle arrest 
and attenuated apoptosis (34, 35).  
 
Regulation of Primary Cilia.  The primary cilium is a microtubule based 
structure that protrudes from the surface of non proliferative cells and functions to 
sense molecular and environmental cues (36).  Primary cilium is important in the 
kidney as loss of primary cilia leads to increased proliferation in tubular epithelial 
cells (reviewed in (37)).  This results in the development of large renal cysts which 
eventually leads to kidney failure (26).  Abhorrently large renal cysts are a prominent 
feature of VHL disease as the epithelial cells lining these cysts are VHL deficient and 
have increased HIF responsive gene expression (38).  Further, the types of VHL 
disease that patients present with are associated with primary cilia formation as well.  
Those with Type 2B VHL disease are highly predisposed to developing ccRCC and 
retain the ability to maintain cilia while those with Type 2A VHL disease (not highly 
predisposed to ccRCC) and Type 1 VHL disease (highly predisposed to developing 
ccRCC) fail to maintain primary cilia (39, 40).  This presents a paradox because 
though VHL patients frequently have loss of pVHL expression, renal cysts are so 
infrequent suggesting that pVHL inactivation alone may not be responsible for 
impaired primary cilium and other signals may play a prominent role as well.  In 
other words, some VHL associated ccRCC cancers may not directly arise from renal 
cysts and though some VHL families may manifest renal cysts, they may be low risk 
and may not necessarily lead to RCC.   
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Consistent with these findings, several groups have shown that pVHL 
specifically localizes to primary cilia and is at least partially HIFα independent, both 
in in vitro and in vivo studies (26, 27, 40).  This was further confirmed in primary cells 
as loss of pVHL does not specifically affect cilia formation in vitro.  However, an 
indirect connection was made to loss of pVHL affecting cilia formation.  GSK3β plays 
a key role in promoting microtubule stability as well as cilium maintenance and this 
role is VHL dependent (41).  When GSK3β is inactive (such as when the PI3K-Akt 
pathway is activated), microtubule stability and cilium maintenance is now 
dependent on VHL expression.  Without VHL expression, cells lose their cilia in 
response to GSK3β inactivation (40).  Cellular disruptions of microtubules causing 
dysregulation of migration and polarity have also been implicated in tumor formation 
(41).  As more VHL associated microtubule connections are discovered, it will be 
interesting to explore if VHL also plays a role, at least partially, in this microtubule 
associated function with cilia formation.   
 
Extracellular Matrix Remodeling.  One of the most clearly documented roles 
emerging in recent years is that of the role of VHL in extracellular matrix remodeling 
at both the organization level as well as with organelles located and associated with 
the ECM.  An elegant study performed within the C. elegans world, where the simple 
nematode has a single VHL and single HIFα homolog, have opened up a wealth of 
information regarding pVHL independent of HIF activities and its role at ECM (28).  
When pVHL was deficient without the interference of HIFα expression, overlapping 
genes responsible for extracellular matrix (ECM) formation including those encoding 
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for procollagen hydroxylases (dpy-18 and let-268) and those that encode for 
secreted metalloproteases (gon-1 and mig-17) were found suggesting a 
commonality between the ECM and pVHL loss (28).  Further, within mammalian 
cells, biochemical evidence suggests that pVHL directly has a role in the assembly 
of the extracellular fibronectic matrix (29).   Molecular evidence directly links pVHL to 
ECM assembly in vivo, as cells lacking VHL expression fail to properly organize the 
extracellular matrix whereas when wild-type VHL was reintroduced into cells, pVHL 
was able to partially restore the ECM phenotype (29, 42).  Additionally, cells mutated 
for VHL have increased expression of the matrix metalloproteinases, MMP2 and 
MMP9, enzymes important for degradation and remodeling of the ECM and also 
upregulate MMP inhibitors such as TIMPs (43).   Extracellular matrix remodeling is 
an important aspect of cancer biology as it provides structural support for cells as 
metastasis has been associated with the destruction of the ECM and now, it is 
distinctly linked to VHL.    
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Figure 1.3: HIF independent functions of pVHL.  pVHL has other activities and functions 
that are important for the features listed below, either activating (arrow) or blocking (block) 
that function.  Below each is the cellular effect with the putative interactive partners.  Figure 
adapted from Moch H, Pathologe 2008 (44). 
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Hypoxia Inducible Factors (HIFs) 
Cellular adaptation to low oxygen conditions (hypoxia) is a survival 
mechanism that most mammalian cells have learned to adapt to for successful 
survival and development.  Indeed, hypoxia is also a common feature of many 
cancers.  Hypoxia in cancer occurs when the tumor outgrows the angiogenic regions 
leading to various areas of the budding tumor having hypoxic regions.  The 
transcriptional response to physiological and pathological hypoxia is primarily 
mediated by two master regulatory hypoxia-inducible factors, HIF-1α and HIF-2α.  
Though these HIF factors are highly homologous in sequence (48%) and structure, 
they share both similar and divergent functions (18, 45, 46).   
 
HIF regulation.  Structurally HIF-1α has a basic helix-loop-helix (bHLH) and 
two tandem PAS domains (N-terminal PAS A and C-terminal PAS B).  HIF-1β (also 
known as aryl hydrocarbon receptor nuclear transporter, ARNT1) also shares similar 
structural characteristics and encodes bHLH and PAS A and PAS B domains, key 
mediators of dimerization between the HIF-α and β subunits (47).  In addition to 
containing bHLH and PAS domains, the HIF-1α subunit also has two transcriptional 
activation domains called TADs whose primary role is to act as recruiters of co-
activators and also interacts with them.  This recruiting function is crucial to the 
transcriptional activation of target genes.  These domains are of additional 
importance as HIF-1α also undergoes post-translational regulation via other 
mechanisms including hydroxylation, phosphorylation and acetylation (48-50).  The 
TADs are further segregated and named by where they are located, at the N-
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terminus (N-TAD) or the C-terminus (C-TAD).  HIF-1α contains an oxygen 
dependent degradation (ODD) domain that regulates protein stability based on 
oxygen levels.  This domain encodes the N-TAD domain and has the two prolyls 
(P402, P577) that are subject to hydroxylation under normal oxygen conditions and 
recruit the pVHL E3 ubiquitin ligase.  The C-TAD domain is responsible for recruiting 
the transcriptional co-activators, Creb-binding protein CBP/p300.  This recruitment is 
oxygen dependent as under normoxia (or normal oxygen conditions); factor 
inhibiting HIF-1α (FIH-1) hydroxylates a conserved asparagine residue (N813) in the 
C-TAD domain preventing interaction with the transcriptional co-activators, 
CBP/p300 (Figure 1.4).    
Similarly, HIF-2α (also known as endothelial PAS domain protein 1, EPAS1) 
also contains a bHLH, PAS (A & B), and TAD (N-TAD & C-TAD) domains.  In fact, 
there is a 48% sequence similarity between HIF-1α and HIF-2α and within the 
specific domains, there is a high sequence homology; bHLH (85%), PAS (70%), 
PAS-A (68%), PAS-B (73%), N-TAD (40%) and C-TAD (69%) domains (51).  
Structurally, HIF-2α is similar to HIF-1α as described above (bHLH, PAS, N-TAD 
and C-TAD domains) with two specific prolyl residues (P405, P530) and a conserved 
asparagine residue (N851) that are subject to hydroxylation, the best characterized 
posttranslational modification.   
However, within the C-terminus is where the major functional differences lie 
between the HIF-1α and HIF-2α subunits.  Though both HIF-1α and HIF-2α can and 
do bind to hypoxic response elements (HREs) of hypoxia response genes, this 
binding is not sufficient for target gene activation (51, 52).  For target gene 
 14
activation, the C-terminal region of HIF-1α and HIF-2α needs to cooperate and 
function with their specific N-terminal region and that cooperation determines 
specificity for gene activation (Figure 1.4). 
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Figure 1.4: Structure of HIF subunits. HIF-1α and HIF-2α are highly similar in structure, 
particularly in their DNA and ARNT binding sites based on amino acid residue similarity.  
Likewise, HIF-1β is highly similar but only has DNA binding and ARNT binding sites that 
heterodimerize with the HIFα subunits.  Figure adapted from Hu et al, Mol Biol Cell 2007 
(51).   
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HIF targets.  HIF-1α is more ubiquitously expressed whereas HIF-2α is 
expressed in a cell-type specific manner (18, 45, 46) specifically within regions 
important for oxygen tensions such as the lung, heart and endothelium.  HIF-1α and 
HIF-2α are expressed in multiple malignant human tumors including breast, ovarian, 
prostate, pancreatic and renal cancers.  Both HIF subunits are subjected to 
dimerization with HIF-1β/ARNT and bind the same sequence (5’-CGTG-3’) with 
hypoxia response elements (HREs), oxygen dependent promoters/enhancers of 
target genes.  Though highly homologous in structure and both bind similar 
sequences, HIF-1α and HIF-2α each transcriptionally activate analogous and 
divergent target genes (8).   
Both HIF-1α and HIF-2α regulate genes important for angiogenesis including 
vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), 
glucose transporter 1 (Glut1) as well as those having significant impact on 
invasion/metastasis including matrix metalloproteinase 2 (MMP2) and the 
chemokine (C-X-C motif) receptor 4 (CXCR4) (8).  However, each subunit uniquely 
induces the upregulation of specific target genes.  HIF-1α induces genes responsible 
for glycolysis including lactate dehydrogenase-A (LDA) and phospho-glycerase 
kinase (PKA) and genes responsible for apoptosis including the pro-apoptotic gene 
BNIP-3 (8, 53).  Conversely, the embryonic transcription factor, Oct-4, shown to be 
important for de-differentiation and stem cell regulation, is the most widely agreed 
upon unique HIF-2α specific target gene (54).  However, there are other genes 
induced predominantly by HIF-2α including erythropoietin (EPO) as well as genes 
responsible for cellular proliferation including Cyclin D1 and Twist1 (53, 55, 56).  All 
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this evidence suggests that though the HIF subunits share similar structures, they 
also have differing functions that diversely affect cellular processes (Figure 1.5).       
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Figure 1.5: HIFs have both shared and unique targets. Though the HIF subunits share 
similar structures, they have divergent functions that diversely affect cellular processes.  
Figure adapted from Gordan JD & Simon MC, Curr Opin Genet Dev 2007 (57). 
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VHL Disease Subtypes Lead to ccRCC  
Within the spectrum of VHL disease, there is a tight genotype-phenotype 
correlation seen among the subtypes corresponding with the severity of disease 
presentation.  The von Hippel-Lindau (VHL) tumor suppressor gene encodes a 
30kDa protein that is mutated in a majority of VHL disease patients.  Those that 
present with VHL disease are predisposed to a variety of cancers including 
pheochromocytoma (adrenal gland tumors), hemangioblastoma (retinal tumors and 
tumors of the central nervous system) and the most lethal, clear cell RCC (58).  VHL 
patients fall into distinct genotypic categories that can predict the spectrum of 
disease risk and phenotypic presentation (59, 60) (Table 1.1). Additionally, VHL 
disease subtypes can further be categorized by their mechanism of HIFα regulation 
(61) (Figure 1.6A).  Type 1 VHL disease is characterized by nonsense mutations, 
frameshift mutations and truncations of VHL (null mutation) and have a high risk of 
ccRCC.   Further, HIFα regulation is completely disrupted in this VHL subtype.  Type 
2 VHL diseases are characterized by missense mutations but can be further 
characterized based on the risk of ccRCC and predicted HIFα regulation.  Type 2A 
disease subtype, designated by the representative mutation (Y112H), is predicted to 
have a low risk of developing ccRCC and disrupt the interaction with the HIFα 
subunit leading to a weak regulation by HIFα (62).  The Type 2B disease subtype 
(R167Q) is predicted to have a high risk of developing ccRCC and has weak HIFα 
regulation as type 2Bs has impaired binding to Elongin C of the pVHL complex (62) 
(Figure 1.6B).  VHL Type 2C disease (L188V) does not confer an advantage to 
developing ccRCC and its interaction with HIFα is predicted to be normally 
 20
regulated.  Together, this suggests a definitive genotype-phenotype correlation 
predictive of ccRCC presentation.  
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VHL Disease 
Subtype 
Likelihood 
of ccRCC 
Representative 
Mutations 
Predicted HIFα 
Regulation 
Type 1 High Null Absent 
Type 2A Low Tyr112His Weak 
Type 2B High Arg167Gln Weak 
Type 2C None Leu188Val Normal 
 
Table 1.1: Genotype-phenotype correlation of VHL disease subtypes. Table showing 
the predicted risk of developing ccRCC, the respective representative mutations and each 
subtype’s predicted interaction with HIFα subunit.  Table adapted from Rathmell et al 
Cancer Res 2004 (61). 
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Figure 1.6: VHL gene structure and predicted HIFα regulation by VHL subtype.   
A. VHL gene structure showing the amino acid positions of the representative mutations. 
Each corresponding VHL subtype is written in red. The region of interaction is shown for 
each VHL subtype: Type 2A to the HIF interaction domain, Type 2B to the Elongin C 
domain, Type 2C to a region of the pVHL α-domain not shown to interact with Elongin C. 
Figure modified from Rathmell et al Cancer Res 2004 (61). 
B. Genotype-phenotype correlation based on predicted HIFα regulation.  Arrow shows 
increasing levels of HIFα expression from green to red (bottom to top).  With higher levels of 
HIFα expression, there is a higher predisposition to ccRCC (shown by the blue rectangle).  
Figure adapted from Kaelin WG Nature Rev Cancer 2008 (63).    
 22
Targeted Therapies for RCC 
Targeted therapy has come into play for the treatment of many cancers.  
Recent developments in the molecular biology of RCC have identified several 
pathways associated with the development of this cancer. This includes the VHL/HIF 
pathway in which several HIF regulated targets such as PDGF and VEGF are 
upregulated and are key regulators of angiogenesis in RCC even though their 
respective receptors, PDGFR and VEGFR, are not present on RCC.  RTK inhibitors 
targeted against many hypoxia target genes and receptors such as VEGFR, PDGFR 
and mTOR have been constructed and are in varying stages of clinical trials and 
approval by the US Food and Drug Administration (FDA).  
Small molecule inhibitors targeted against the tyrosine kinase domains of 
intracellular receptors have burst onto the clinical landscape and are currently 
primarily utilized within clinics across the US.  In fact, within the past 5 years, the 
FDA has approved 4 drugs for the treatment of RCC - two antiangiogenic agents, 
sorafenib and sunitinib and two mTOR inhibitors, temsirolimus and everolimus (13).   
Sorafenib (Nexavar®, Bayer Pharmaceuticals and Onyx Pharmaceuticals) 
was originally developed as a Raf kinase inhibitor.  It has since been shown to be a 
potent inhibitor of multiple kinases including VEGFR-2, VEGFR-3 and PDGFR-β (11) 
and is an orally available agent shown to significantly inhibit RCC tumor growth and 
prolong overall survival.  In support of this, numerous clinical trials have been 
conducted and show that treatment with sorafenib has significant clinical benefit and 
improves patient survival by several months when compared to placebo (9, 10). This 
is significant for the treatment of RCC as this disease is notoriously difficult to treat.  
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Additionally, sunitinib (Sutent®, Pfizer Inc), an antiangiogenic and antitumor drug, 
has also shown efficacy in RCC.  Sunitinib inhibits multiple kinases including the 
VEGFRs, FMS-like tyrosine kinase 3 (FLT3), PDGFR and c-KIT.  In various clinical 
trials, RCC patients treated with sunitinib have both reduced tumor mass as well as 
tumor growth inhibition compared to the control treatment interferon alpha (11, 12).   
A third inhibitor approved for the treatment of RCC is the mTOR inhibitor, 
temsirolimus, a water-soluble ester of rapamycin.  A survival advantage has been 
shown with the use of temsirolimus in comparison with interferon-alpha in advanced 
stage, poor-prognosis RCC patients (64).  Another mTOR inhibitor recently 
approved for RCC treatment in March 2009 is everolimus (RAD001, Novartis).  
Everolimus binds to FKBP12 with high affinity and the everolimus-FKBP12 complex 
inhibits downstream mTOR signaling (65) including genes regulated by HIF-1α.  
Everolimus has been shown to improve progress-free survival in clinical trials when 
compared to the placebo (12).     
With the advent of RCC treatments, several guidelines have been 
recommended in support of when to administer the drug to RCC patients.  Sunitinib 
is recommended as a first line of treatment for patients who are at low or 
intermediate risk for metastatic RCC.  Sorafenib is suggested as a second line of 
treatment while temsirolimus is suggested as a first line of treatment for patients who 
are at high risk for metastatic RCC (66).   Additionally, other inhibitory agents have 
also shown efficacy for the treatment of RCC and are currently being investigated for 
their efficacy in treating RCC.   An example of this is Bevacizumab (Avastin®, 
Genentech/Roche) which is a humanized monoclonal antibody that targets VEGF 
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and improves progression-free survival in RCC patients and is suggested for use as 
a second line of treatment (67).  
Although inhibitor treatment options exist for RCC (Figure 1.7), there is still 
room for drug target optimization for clinical relevance and further patient benefit.  
Within the last several years, certain targeted therapies have been shown to have a 
better end effect depending on the kinase targeted.  This could be because cancers 
have developed an “oncogenic addiction” in which tumors come to depend on 
certain cell signaling pathways.  Some examples of targeting the tumor kinase rather 
than the tumor supporting cells include the use of gefitinib to target the mutated form 
of the EGFR for non-small cell lung cancer treatment which causes durable disease 
remissions in patients with EGFR kinase domain mutations (68).  Another example 
of targeting a cell intrinsic kinase rather than tumor supporting cells is the use of 
sunitinib, which targets the mutated form of c-kit in the gastrointestinal stromal tumor 
(GIST) (69).  When this cell-intrinsic mutant kinase is targeted, a dramatic and 
durable reduction in tumor burden is seen.  However, this illustrates a gap in the 
RCC field as there are no known reported tumor cell intrinsic kinase targets 
expressed on RCC.    
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Figure 1.7:  Targeted therapies currently in use for treating RCC.  Figure adapted from 
Rathmell WK, Wright TM & Rini B Expert Rev Anticancer Ther 2005 (19). 
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Ror2 
The receptor tyrosine kinase-like orphan receptor 2 gene is part of a family of 
orphan RTKs that includes Ror1 and Ror2 and contains 9 exons (9q22) (70, 71).  
Ror2 is evolutionary conserved across several species including C. elegans, 
Drosophila, Xenopus, mice and humans.  In fact, there is a 92% amino acid identity 
between mouse and human Ror2.  Ror2 is characterized by an intracellular tyrosine 
kinase domain, which is highly related to the Trk-family RTKs and muscle specific 
kinase (MuSK) (72).  Ror2 also contains a proline rich domain flanked by serine-
threonine rich domains.  Proline rich domains have previously been shown to be 
important for phosphorylation and protein interactions (73), however the role of 
proline rich domains in Ror2 have not been fully elucidated.  The extracellular 
domain contains an Ig-like domain, a Frizzled-like cysteine-rich (CRD) domain, 
which has been shown to act as receptor for Wnt, and a Kringle domain (Figure 1.8) 
(74).  During mouse development, Ror2 expression is seen in the face, limbs, heart, 
brain and lungs (75-78).   
In C. elegans, only one Ror gene exists as compared to the two normally 
found in mammals.  Through mutational analysis, the C. elegans Ror2 ortholog 
CAM-1 has been shown to direct correct cellular orientation and migration (79).  
Mouse Ror2 (mRor2) knockout mice have also been engineered by two independent 
labs.  The neomycin resistance gene (neoR) was used to replace the Ig domain in 
one group (77), while the other group used neoR and lacZ to replace the tyrosine 
kinase domain (71).  Similar phenotypes were observed from these two groups.  
Heterozygote mRor2 were phenotypically wildtype (WT) while homozygote mRor2 
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knockouts died shortly after birth.  Further, mRor2 deficient mice had atypically short 
limbs and tails, malformed facial and vertebrae features and respiratory defects (71, 
77).   
Two human genetic disorders also arise from mutations in human Ror2 
(hRor2).  Short-limbed dwarfism and abnormal facial features are characteristic of 
autosomal recessive Robinow syndrome, which arises from missense, nonsense 
and frameshift mutations in the CRD, kringle and kinase domains of hRor2.  This is 
similar to phenotypes observed in Ror2 mutant mice suggesting that Robinow 
syndrome may be caused by a loss-of-function (LOF) mutation of Ror2 (80-82).  The 
autosomal dominant inherited disorder Brachydactyl type B (BDB) arises from 
mutations resulting in the truncation of hRor2 by either (1) loss of the entire kinase 
domain after the membrane spanning region or (2) loss of the serine/threonine and 
proline-rich domain just below the tyrosine kinase domain.  In this disorder, 
individuals’ bones are shortened or misshapen because of endochondral bone 
ossification (71, 80, 83). 
Ror2 has also been implicated in the Wnt signaling pathway.  In both 
canonical and noncanonical Wnt signaling, the Wnt proteins bind to the Frizzled (Fz) 
family of cell-surface receptors along with the co-receptor protein LDL-receptor-
related protein (LRP5 and 6).  However, in classic canonical Wnt signaling, binding 
of the Wnt protein to Fz and LRP leads to LRP phosphorylation, activates the 
cytoplasmic signaling protein Dishevelled (Dsh) and blocks GSK3β phosphorylation, 
which is now incapable of phosphorylating β-catenin.  Unphosphorylated cytosolic β-
catenin accumulates and translocates to the nucleus, driving the transcription of 
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numerous target genes by displacing the co-repressor protein Groucho from TCF.  
Without Wnt signaling, Dsh is inactivated and no longer able to block GSK3β 
phosphorylation.  GSK3β phosphorylates cytosolic β-catenin, tagging it for 
ubiquitination and is then degraded by the proteasome.   In planar cell polarity (PCP) 
noncanonical Wnt signaling, after Fz is activated, Dsh linked to disheveled-
associated activator of morphogeneis 1 (Daam1) activates JNK via Rac to regulate 
cellular orientation.   
Recent work shows that the CRD and proline rich domain of mRor2 are 
required to induce noncanonical Wnt5a mediated cellular migration (84).  Along the 
same line, there is evidence suggesting that mRor2 can also activate the Wnt/JNK 
pathway and inhibit Xenopus convergent extension movements via the noncanonical 
Wnt5a pathway (85).  One proposed mechanism suggests that when the 
representative noncanonical Wnt5a ligand interacts with mRor2, canonical Wnt/β-
catenin pathway is inhibited downstream of β-catenin stabilization at the level of 
TCF-mediated transcription (86).  Another proposed mechanism hypothesizes that 
hRor2 inhibits the ability of the canonical Wnt1 and Wnt3 ligands to stabilize β-
catenin (Figure 1.9).  Wnt1 activates an unidentified signaling cascade which in turn 
activates Wnt-responsive promoter activity.  On the other hand, Wnt3 activates other 
Tyr kinase dependent events and causes the inhibition of Wnt-responsive promoters 
(87). Although the above information is available in current literature, how Ror2 
functions in the context of RCC had yet to be determined.      
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Figure 1.8: Structural Representation of Ror2.  Ror2 is characterized by an intracellular 
tyrosine kinase (TK) domain which is highly related to the Trk-family RTKs and muscle 
specific kinase (MuSK) and a proline-rich (PR) domain flanked by serine-threonine (SR) 
domains.  The extracellular and intracellular domain are separated by the transmembrane 
domain (TM) and contains an immunoglobin-like (Ig) domain, a Frizzled-like cysteine-rich 
(CRD) domain, which has been shown to act as receptor for Wnt in other proteins, and a 
Kringle domain (Kr). 
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Figure 1.9: Proposed Mechanisms of Ror2 actions.  Several mechanisms have been 
proposed for the actions of Ror2.  Ror2 binds Wnt and sequesters them away from frizzled 
receptors inhibiting their ability to stabilize ß-catenin.  Wnt1 binding to Ror2 activates an 
unidentified signaling cascade requiring Tyr Kinase activity and activates Wnt-responsive 
promoter activity.  Wnt3 binding to Ror2 activates other Tyr kinase dependent events that 
inhibits Wnt-responsive promoters.  When Wnt5a interacts with mRor2, the canonical Wnt/β-
catenin pathway is inhibited downstream of β-catenin stabilization at the level of TCF-
mediated transcription. Figure adapted from Gordon and Nusse J Biol Chem 2006 (88) and 
Billiard et al Mol Endocrinology 2005 (87).   
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Ror2 and Cancer 
At the time of discovery of Ror2 in RCC in 2006, aberrantly expressed Ror2 
had not been described in any cancer.  Since then, the landscape of Ror2 in cancer 
has changed dramatically.  To date of writing this thesis, the developmentally 
regulated kinase Ror2 has been described as overexpressed in a variety of cancers 
including melanoma, squamous cell carcinoma and gastric cancer (Table 1.2).   
Via cDNA microarray analysis, O’Connell et al (89) recently found that Ror2 is 
expressed in a majority of metastatic melanomas.  Previous data has shown that 
Wnt5 has a role in Ror2 signaling and, in fact, O’Connell and colleague’s previous 
data suggests that the noncanonical Wnt ligand Wnt5a may be an important aspect 
of melanoma tumorigenesis.  Indeed, Wnt5a expression correlated with Ror2 
expression – when Wnt5a was increased so was Ror2 expression and when Wnt5a 
levels were decreased, it also led to a decrease in Ror2 expression.  However, when 
Ror2 levels were decreased, Wnt5a levels remained constant but there was a 
decrease in Wnt5a downstream signals.  When Ror2 expression was suppressed, 
there was a drastic reduction in cell motility, cellular invasion and metastasis in the 
melanoma cell lines examined.  This work clearly suggests that Ror2 has a role in 
Wnt5a mediated invasion in metastatic melanoma.   
Ror2 has also been implicated in osteosarcoma, a malignant adolescent bone 
cancer (90).  Utilizing cDNA microarrays, Morioka et al (90) found Ror2 to be 
transactivated in a majority of osteosarcoma malignancies.  Upon further analysis of 
Ror2 expression in osteosarcoma, Ror2 suppression exhibited reduced cellular 
migration and proliferation.  Additionally, using two osteosarcoma cell lines (SaOS-2 
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and U2OS cells), Enomoto et al (91) show that cellular migration is mediated by the 
expression of Ror2 and its potential receptor/co-receptor, Wnt5a.  With the 
suppression of either Ror2 or Wnt5a, cellular invasion was inhibited.  Further, with 
the suppression of Ror2, they identified a matrix metalloproteinase, MMP13 - shown 
to be important for extracellular matrix (ECM) regulation and invadopodia (actin-rich 
protrusions that degrade and extend into the ECM) formation.  Their data 
emphatically suggests that MMP-13 expression induced by Wnt5a/Ror2-mediated 
expression is important for cell migration, ECM degradation and invadopodia 
formation.  Together, these data place Ror2 as having an important role in malignant 
osteosarcoma.   
Ror2 was also identified in squamous cell carcinoma by Kobayashi and 
colleagues (92) as being more highly expressed in oral malignant cancer epithelial 
cells compared to normal mucosa.  In squamous cell carcinoma, Ror2 expression 
paralleled the development of invasive features of these tumors.  Further, this study 
indicates that in squamous cell carcinoma, Ror2 expression is associated with cell 
motility and cell polarity.   
Additionally, Ror2 has also been identified in poorly differentiated invasive 
gastric cancers by a tumor genomic analysis as a frequent target of non 
synonymous mutagenesis (93).  An additional study by Ohta and colleagues (94) 
identified Ror2 as one of the genes upregulated downstream of Hedgehog (Hh) and 
epithelial to mesenchymal transition (EMT) signaling in their search for potential 
gastric cancer molecular targets.  In the large majority of intestinal-type and diffuse-
type gastric cancers tested, Ohta et al identified the EMT regulator, SIP1, as a target 
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of Hh signaling and as a regulator of downstream Ror2 expression.  Using siRNA, 
they show that SIP1 directly reduces gastric cancer cell invasion.  Additionally, they 
show distinctly that Ror2 is a cancer-specific target of Hh and EMT signaling tying 
the expression of Ror2 to another malignant cancer.      
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Group Cancer Role of Ror2 
O’ Connell et al (89) Metastatic Melanoma * Metastasis 
* Cell Migration 
* Wnt5a mediated signaling 
Morioka et al (90) Osteosarcoma * Cell Migration 
* Cell Proliferation 
Enomoto et al (91) Osteosarcoma * Cell Migration  
* Invadopia Formation  
* ECM Degradation 
Kobayashi et al (92) Squamous Cell Carcinoma * Cell Polarity  
* Cell Motility 
* Malignancy 
Kubo et al (93) Gastric Cancer  * Ror2 mutated in activation 
domain 
Ohta et al (94) Gastric Cancer  * Cell invasion  
* Downstream of crosstalk 
between Hh and EMT 
signaling 
 
Table 1.2: Role of Ror2 in a variety of cancers. 
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Significance 
Treatment alternatives for RCC are sought as this is a complex disease with limited 
traditional management options.  Targeted therapy for RCC has recently come into 
play as targeted therapeutics have been shown to cause disease stabilization and 
prolong survival by several months.  However, tumor cell intrinsic targets for RTK 
inhibition remain elusive.  In studying the role of the novel kinase Ror2 in RCC, I 
hope to provide a new potential target for pharmacological inhibition in RCC.  This 
thesis provides the characterization tools necessary to shed light on a target that has 
the additional potential to be used as a pharmaceutical biomarker for clinical 
treatment of RCC.  
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DISCOVERY AND VALIDATION OF ROR2 AS A RCC CANCER CELL SPECIFIC 
KINASE 
 
 
 
 
 
 
 
 
 
 
 
 
 
This work is modified from: Wright et al (2009) Oncogene (1) 
 
 
ABSTRACT 
Abhorrent kinase activity is a defining feature of many solid malignancies, and the 
recent widespread introduction of receptor tyrosine kinase (RTK) inhibitors into the 
mainstream treatment of cancer has revolutionized the practice of oncology.  
However, the potency of a kinase-directed treatment can only be as effective as the 
activity of the target.  Thus, the identification of novel target molecules has the 
potential to rapidly and durably impact tumor growth for the treatment of patients 
with cancer.  Here we identify Ror2, an orphan receptor tyrosine kinase previously 
unrecognized as an epithelial cancer-related kinase, to be upregulated in renal cell 
carcinoma (RCC) cell lines and tumor samples.  Ror2 is normally repressed in adult 
tissue; however this study identifies, Ror2, a developmentally regulated kinase, to be 
overexpressed in RCC for the first time.  
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INTRODUCTION 
Sporadic renal cell carcinoma (RCC) is a notoriously difficult to treat solid 
tumor malignancy that has minimal sensitivity to traditional chemotherapy and 
immune system modulation.  Affecting over 40,000 individuals in the US each year 
(2), this disease is highly refractory to conventional cytotoxic therapies.  The majority 
of clear cell histology RCC tumors are characterized by mutation, methylation, or 
loss of the VHL gene rendering them deficient in the pVHL protein (3-6).  One well-
documented function of pVHL is to act as the substrate recognition component of an 
E3 ubiquitin ligase complex (7-10).  The substrates of pVHL E3 ligase activity most 
tightly associated with RCC are the hypoxia inducible factor (HIF)-α subunits (HIF-1α 
and HIF-2α) (11-13).  As a result of VHL inactivation in RCC, one or both of these 
factors are stabilized and transcriptionally activated in the tumor cells, regulating a 
large panel of hypoxia responsive genes (14, 15).  This transcriptional response 
leads to the phenotypic characteristics of RCC and at least a component of the 
transformed phenotype of the cells (16).   
As RCC is relatively refractory to conventional therapies, recent advances for 
the treatment of RCC have come in the form of multitargeted kinase inhibitors 
implicating kinase signaling as a potential viable area for further development.  In 
this study, we sought to identify activated tumor specific kinases expressed on RCC 
cells in order to discern active signal transduction pathways available for targeted 
therapy development.  To do so, we utilized a phospho-RTK array with RCC cell 
lysates to identify tumor cell specific activated in RCC.   
 49
We report the identification of a novel Wnt receptor of embryonic 
mesenchymal origin expressed in RCC cell lines and tumors. The receptor tyrosine 
kinase-like orphan receptor 2 (Ror2) gene is part of a family of orphan RTKs that 
includes Ror1 and Ror2 (17).  Ror2 is characterized by an intracellular tyrosine 
kinase domain (18) and an extracellular Frizzled-like cysteine-rich domain (CRD), 
shown to act as receptor for Wnt (19).  Mouse Ror2 (mRor2) expression is normally 
observed in the developing heart, brain and lungs (20-23), with the greatest 
expression seen in the migrating neural crest and mesenchymal tissues (23).   
By immunoblot and qRT-PCR, we show that Ror2 is expressed in multiple 
renal carcinoma cell lines.  In addition, we detected Ror2 transcripts in more than 
55% of a set of 19 archival human RCC tumor specimens.  Further, we were able to 
detect protein expression in primary RCC tumors. This definitively identifies and 
confirms the expression of Ror2 in RCC validating the need for further 
characterization of this kinase in RCC.       
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RESULTS 
Identification of a novel kinase in RCC 
As inappropriate kinase expression is a hallmark of many cancers and offers 
insight into essential signaling pathways of tumor pathogenesis, we sought to 
identify profiles of activated kinases in RCC cell lines.  Kinases that facilitate 
essential activities of the tumor can provide important and effective targets for 
inhibitor therapy; therefore, a phosphorylated-tyrosine kinase array was used as a 
screen to identify kinases with a basal level of tyrosine phosphorylation in 
unstimulated RCC lysates.   
Currently, there are no known disease-associated cell intrinsic kinases for 
RCC.  Our initial goal was to identify cancer cell specific kinases expressed on RCC 
as rational targets for pharmaceutical development.  Since the majority of RCC 
tumors are characterized by VHL mutation rendering them VHL deficient, we utilized 
the well-established RCC tumorigenic cell line 786-0 RC3, a derivative of the 
parental 786-0 RCC cell line created by introduction of an empty vector for the initial 
studies.  The parental 786-0 cell line contains a mutation in the VHL gene so pVHL 
is not produced (Table 2.1).  In this cell line, only HIF2α is deregulated.  HIF2α is 
considered to be the more tumorigenic of the two HIFα subunits as downregulation 
of HIF2α is necessary for tumor suppression by pVHL (16, 24, 25).  We utilized the 
human phospho-receptor tyrosine kinase (RTK) array (RND Systems - Minneapolis, 
MN) to assess the relative phosphorylation changes in our cells as this offers a more 
sensitive measure of relative phosphorylation levels.  In this assay, antibodies 
targeted against 42 RTKs are spotted in duplicate on nitrocellulose membranes.  
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786-0 RC3 cell lysates were diluted and placed on the nitrocellulose membranes.  
After the cell lysates were bound to the extracellular domain of both phosphorylated 
and unphosphorylated antibodies, phosphorylated RTKs were visualized using an 
anti-phosphorylation antibody conjugated to horse radish peroxidase.  
Chemiluminescence was used to detect the activated RTK antibodies according to 
the manufacturer’s instructions.   
With this assay, we observed the presence of activated kinases known to be 
present on RCC such as epithelial growth factor receptor (EGFR). Additionally, we 
were able to confirm the absence of active vascular endothelial growth factor 
receptor (VEGFR) and platelet-derived growth factor receptor (PDGFR) on RCC 
cells.  Though several potential kinases were identified from this phospho-RTK 
screen, we chose to move forward with Ror2, a receptor tyrosine kinase-like kinase 
previously unknown in renal carcinoma cells (Figure 2.1) as it was the most novel at 
the time and had not been identified in any cancer. 
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Figure 2.1: Human Phospho-RTK array screen for activated kinases in RCC. 
Human Phospho-RTK array screen for activated kinases in RCC.  Utilizing a phospho-RTK 
array, 42 RTKs were screened for phosphorylation in RCC using the 786-0 RC3 cell line.  
Activated kinases were identified using an HRP-conjugated pan-phosphotyrosine antibody.  
From this screen, one novel RTK identified was Receptor Tyrosine Kinase-like Orphan 
Receptor 2 (Ror2).  Additional spots demonstrating positive identification include a kinase 
known to be activated in RCC cells (EGFR) and negative control spots (Goat IgG).   
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Verification of Ror2 activity in RCC 
Physiological expression of Ror2 in adult tissues had not previously been 
shown at the time of Ror2 discovery in RCC, with the exception of osteoblasts (26).  
Abundant expression of the endogenous protein in 786-0 RC3 cells was confirmed 
by immunoblot analysis and immunoprecipitation of Ror2 with independent 
antibodies (Figure 2.2).   Detecting phosphotyrosine from the immunoprecipitation 
using a nonspecific phospho-tyrosine antibody (pY99), further confirmed that the 
kinase is phosphorylated under basal conditions.  Similarly, Ror2 protein was not 
detectable in lanes controlling for antibody isotype and nonspecific activity of the 
resin.  These data substantiate the detection of Ror2 protein, the activation of Ror2 
kinase in RCC and merits further analysis.  
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Figure 2.2: Verification of Ror2 activity in RCC cells.   
Expression and phosphotyrosine activation of Ror2 is confirmed by immunoprecipitation 
from RCC cells.  Ror2 protein was immunoprecipitated from 786-0 RC3 cells using biotin-
conjugated goat Ror2 antibody for antigen retrieval and streptavidin conjugated agarose 
beads.  Immunoblot was performed with an alternate isotype-specific Ror2 antibody to 
confirm the capture of Ror2 and the nonspecific pY99 antibody used to assay for 
phosphotyrosine activity.  Individual lanes show protein detected by immunoblot on (1) 
whole cell extract (input protein), (2) Ror2 immunoprecipitate, (3) isotype-matched 
nonspecific antibody immunoprecipitate and (4) no antibody control.   Ror2 protein was not 
detectable in lanes controlling for antibody isotype and nonspecific activity of the resin.   
Detecting phosphotyrosine from the immunoprecipitation using a nonspecific phospho-
tyrosine antibody (pY99), further confirms that the kinase is autophosphorylated under basal 
cell culture conditions.  
 
 
 
 
              VHL       HIF1α      HIF2α     Glut1 
786-0      -     N/A           +     + 
786-0 RC3     -     N/A           +     + 
786-0 WT8    +     N/A            -     - 
RCC4 2-1           -       +           +     + 
RCC4 3-14    +        -            -                - 
HKC     +        -            -                - 
 
1: Input Protein 
2: Ror2 IP 
3: Nonspecific IP 
4: Bead Only IP 
 
 
 
 
 
 
Table 2.1: RCC tumor cell lines used for Ror2 analysis (expression under normal 
oxygen conditions).   
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Ror2 expression is seen in multiple RCC cell lines 
Since Ror2 was expressed in the 786-0 RC3 cell line, we also wanted to 
assay for expression in other RCC cell lines.  To validate the expression of Ror2 in 
RCC, we utilized two independent antibodies targeting the extracellular domain of 
Ror2: 1) a monoclonal antibody that works under nonreducing conditions and; 2) a 
polyclonal antibody that works under both nonreducing and reducing conditions 
(RND Systems - Minneapolis, MN).  We used the parental 786-0 cell line as well as 
its empty vector containing derivate 786-0 RC3, both of which overexpress HIF2 and 
lack functional pVHL (27, 28).  We also utilized another RCC cell line, RCC4 2-1 
which overexpresses both HIF1α and HIF2α and lacks functional pVHL under both 
normal and low oxygen conditions.  The HKC cell line is a control SV40 transformed 
proximal tubule epithelial kidney cell line which has functional pVHL (Table 2.1).  Our 
results show that the expression of Ror2 is seen in all the RCC cell lines examined 
except the human proximal tubule cell line HKC suggesting that Ror2 is expressed in 
multiple RCC cell lines but not in the normal control.  This result is seen with both 
the monoclonal and polyclonal antibodies targeting Ror2 (Figure 2.3).  The 
expression of Ror2 was further confirmed by qRT-PCR as elevated mRNA levels 
were also detected in these cell lines (data not shown).   
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 Figure 2.3: Confirmation of Ror2 protein expression in RCC cell lines.   
Ror2 is expressed in RCC cells but not in a normal kidney cell line.  Whole cell extracts were 
immunoblotted with monoclonal Ror2, top, polyclonal Ror2, middle, and loading control (LC), 
bottom.  Ror2 expression is seen predominantly in the RCC cell lines, 786-0, 786-0 RC3 
and RCC4 2-1, but not in the proximal human tubule cell line, HKC, using 2 different 
antibodies targeting the extracellular domain of Ror2.   
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Ror2 expression in human RCC tumors  
Ror2 is a developmentally regulated kinase, with expression primarily 
relegated to embryonic mesenchymal tissues (23).  To examine a possible role in 
malignant tissue, Ror2 mRNA expression was analyzed by RT-PCR in 19 primary 
human RCC tumors.  Four representative tumor specimens are demonstrated in 
Figure 2.4A with the HPRT gene used as a control for RNA abundance and integrity.  
The band detected as Ror2 in Figure 2.4A was purified and sequenced, confirming 
identity to the Ror2 CRD domain as predicted (data not shown).  Overall, Ror2 
transcript was detected in more than 55% of an unselected set of archival renal 
tumors (Figure 2.4A).  Ror2 mRNA was detected even in some tumors of non-clear 
cell histology, suggesting that various genetic mechanisms may have the potential to 
promote the induction of Ror2 in renal cancers.   
Detecting Ror2 expression in a malignant context prompted an evaluation of 
Ror2 expression in the normal human kidney.  Ror2 is well known to be expressed in 
developing tissues with expression often restricted to mesenchymal cells (23).  
Consistent with this profile, Ror2 protein was detected in human fetal kidneys in the 
migrating nests of mesenchymal cells that give rise to the bulk of the cell types of the 
developing kidney (Figure 2.4B).   
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33.3% Other RCC expressing Ror2 (1/3) 
66.7% Papillary RCC expressing Ror2 (4/6) 
60.0% Clear Cell RCC expressing Ror2 (6/10) 
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Figure 2.4: Ror2 expression in human RCC tumors. 
A. RT-PCR of archival human tumor samples shows mRNA expression of Ror2.  Nineteen 
(19) archival tumor samples from the UNC Tumor Bank (1994-2004) were amplified with 
primers against the CRD domain of Ror2 (HPRT gene used as a control to assess quality of 
RNA).  Direct sequencing of the PCR product confirmed the product as Ror2.  
Representative examples of Ror2 expression seen in RCC tumors are shown.  A tabular 
distribution of tumors expressing a Ror2 transcript is shown for the individual RCC 
histological subtypes. 
B. Ror2 is expressed in fetal kidney tissues.  Left panel, H&E stain of fetal kidney, Middle 
panel, Ror2 expression detected by immunohistochemistry on primitive migrating 
mesenchymal cells, Right panel, CD117 is used as a negative control for staining specificity 
in the fetal kidney and (expected to be negative as shown) is a control for staining specificity 
for the secondary antibody.   
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Ror2 protein expression in human RCC tumors 
As Ror2 mRNA expression was found in RCC tumors, we asked if Ror2 could 
also be identified at the protein level.  Protein expression of Ror2 was analyzed by 
immunostaining two tumors demonstrating high levels of Ror2 transcript and two 
Ror2 transcript-negative tumors (one representative Ror2 negative tumor shown).  
Hematoxylin and eosin (H&E) serial sections demonstrate the clear cell histology of 
each of these tumors and lack of significant non-tumor cell infiltration.  
Immunofluorescent detection of Ror2 demonstrates tumor cell specific expression of 
Ror2 protein (Figure 2.5).  The immunofluorescence signal was undetectable in 
tumors identified as lacking Ror2 mRNA expression based on the RT-PCR 
evaluation, or in the absence of Ror2 primary antibody.  Nuclear stain shown from 
the same field demonstrates the presence of cellular constituents.  Ror2 protein is, 
therefore, present in a subset of primary RCC tumors and can be detected 
specifically on the tumor cells of the specimen. 
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Figure 2.5:  Protein expression of Ror2 in human RCC tumors. 
Three individual RCC tumors were stained to determine the cellular expression of Ror2.  
H&E of the 3 tumors verifies clear cell histology.  Two tumors were selected having high 
expression of Ror2 transcript (+), and a third tumor identified as having undetectable levels 
of Ror2 transcript (-) was used to verify antibody specificity.  An Ror2 antibody was used to 
assay for Ror2 expression in the RCC tumors.  Top and middle panels show that Ror2, a 
transmembrane cell surface receptor, is mainly expressed in the cell surface or cytoplasm, 
with no detectable protein in the control tumor in the bottom panel.  Control panels show 
negative staining in the no primary control.  DAPI is included for both primary and no primary 
antibody stained sections to demonstrate nuclear staining.  All pictures were taken at 20X 
and the black bar represents 34 uM.  
 
 
 61
DISCUSSION 
In this study, we were interested in identifying activated tumor specific 
kinases expressed on RCC cells.  Using this information, we hoped to identify active 
signal transduction pathways that could be used for targeted therapy development in 
the future.   
We exploited the properties of RCC where the majority of clear cell histology 
RCC tumors are mutated for VHL by utilizing a transformed RCC cell line with 
mutated VHL for our initial studies.  We identified Ror2, a developmentally regulated 
orphan kinase.  Ror2 is physiologically expressed primarily on embryonic 
mesenchymal cells, and is developmentally expressed on migrating mesenchymal 
cells of the fetal kidney.  This kinase was recognized as an activated tyrosine kinase 
in RCC cancer cell lines and renal tumors.  The aberrant expression of Ror2 in 
human tumors had not been specifically described at the time of Ror2’s discovery in 
RCC, although evidence of active Ror2 has been observed on kinase arrays from 
glioblastoma cell lines (29).  In this study, however, we show that Ror2 expression 
was detected in the majority of human RCC tumors, and protein expression was 
confirmed at the tumor cell level.  These data support the identification of a tumor 
cell intrinsic receptor tyrosine kinase, which is usually limited to developing 
mesenchymal cell subsets, that is detectable on the majority of renal cell 
carcinomas.   
As a protein not expressed in other adult tissues, Ror2 has the potential to be 
used as a molecular biomarker for RCC to provide a target for tumor cell 
identification, tumor imaging, or tumor cell-directed systemic therapy.  Ror2 provides 
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another signaling event in the development of RCC and may represent a viable 
target for tumor-directed treatment for patients with RCC suggesting that further 
characterization is warranted.   
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MATERIALS AND METHODS 
Human Phospho-Receptor Tyrosine Kinase (RTK) array 
A human phospho-RTK array kit (RND Systems, Minneapolis, MN) was utilized to 
determine the relative phosphorylation levels of RTKs according to the 
manufacturer’s instruction.  The array consists of antibodies targeted against forty-
two different RTKs spotted in duplicate on nitrocellulose membranes.  786-0 RC3 (a 
control vector-transfected derivative of the VHL mutant RCC cell line 786-0) cell 
lysates were diluted and incubated with the Phospho-RTK array.   Phosphorylated 
RTKs were identified with a pan anti-phospho-tyrosine horseradish peroxidase 
conjugated antibody and activated receptors detected using ECL-Plus 
chemiluminescence reagents (GE, Pittsburg, PA).   
 
Cell Culture 
786-0 and RCC4 cell lines and their derivatives, including the paired cell lines 786-0 
WT8 and 786-0 RC3 (kindly provided by Dr. W. Kaelin, Boston, MA), RCC4 2-1 and 
RCC4 3-14 (kindly provided by Dr. M.C. Simon and Dr. B. Keith, Philadelphia, PA), 
were maintained in Dulbecco’s Modified Eagle Medium (DMEM) with 10% fetal 
bovine serum (FBS), L-glutamine and non essential amino acids.  The HKC cell line 
(kindly provided by Dr. L. Racusen, Baltimore, MD (30)) was maintained in 
DMEM/F12 supplemented with 10% FBS. 
 
Immunoblotting 
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Cells were lysed in whole cell extraction buffer containing 20mM Tris, 100mM NaCl, 
1 mM EDTA, 1% NP-40 and a protease inhibitor cocktail (Roche Diagnostics, 
Indianapolis, IN).  Bradford reagent was used to assess the concentration using 
standard absorbance.  Protein samples were size separated on 8% SDS-
polyacrylamide gels and transferred to nitrocellulose membrane (GE, Pittsburg, PA).  
The following antibodies were used to assess for expression: Monoclonal Ror2 at 
1:250 (RND Systems, Minneapolis, MN), Polyclonal Ror2 at 1:3000 (RND Systems, 
Minneapolis, MN) and Ku80 at 1:2000 (Genetex Inc, San Antonio, TX) as a loading 
control (LC).  The appropriate horseradish peroxidase conjugated secondary 
antibodies were used and proteins detected using ECL-Plus chemiluminescence 
reagents (GE, Pittsburg, PA).   
 
Immunoprecipitation   
500μg of cell lysates were immunoprecipitated using a polyclonal biotinylated Ror2 
antibody (RND Systems, Minneapolis, MN), Epo (N-19) nonspecific IgG goat 
antibody (Santa Cruz, Santa Cruz, CA) and a bead only control per standard 
protocol.  Immunoblotting was then performed as described above using monoclonal 
Ror2 at 1:250 (RND Systems, Minneapolis, MN) and pY99 anti-phosphotyrosine at 
1:1000 (Santa Cruz, Santa Cruz, CA) with 50μg whole cell extract control as input.   
 
RT-PCR Analysis  
Primers targeted against the CRD domain of Ror2 (Left primer: 5’ 
tttcaggatgattaccacgag 3’, Right Primer: 5’ ctcacacttgggcagctgaa 3’) were generated.  
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The following protocol was used to generate the PCR fragment: 94°C for 2 minutes 
(1x), 94°C for 30 seconds, 61.5°C for 30 seconds, 72°C for 30 seconds (34x) and 
72°C for 5 minutes (1x).  The Ror2 CRD domain PCR fragment was confirmed by 
bidirectional DNA sequencing in RCC cells and by BLAST sequence homology 
analysis (data not shown).  Standard HPRT primers (Left primer: 5’ 
cctgctggattacatataagcactg 3’, Right primer: 5’ gtcaagggcatatccaacaacaaac 3’) were 
used to analyze the integrity of the RNA.   
 
Immunohistochemistry and Immunofluorescence   
Formalin fixed and paraffin embedded clear cell RCC tumor blocks were obtained 
from the UNC Tissue Procurement Facility tumor bank (1994-2007) following 
approval of this research by the Institutional Ethics Review Board.  Tissue blocks 
were serially sectioned at 5um thickness onto unprepared glass slides. The first 
section was stained with hematoxylin and eosin (H&E) for tumor verification.  The 
slides were deparaffinized, rehydrated in graded ethanol, and incubated with the 
primary mouse anti-human Ror2 monoclonal antibody (generated by Drs. Mikels and 
Nusse).  A biotin conjugated secondary anti-mouse antibody, avidin biotin 
conjugated horseradish peroxidase antibody, and Fluorophore Tyramide were used 
for human RCC tumor staining according to the instructions of the TSATM-plus 
Fluorescien System Kit (NEL 741001 KT from PerkinElmer Labs, Inc, Waltham, MA).  
Slides were then mounted with Vectashield (H-1200, Vector Laboratories, 
Burlingame, CA) and assayed using fluorescence microscopy.  Immunofluorescent 
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images were taken at 20X magnification at the exposure specified (100 or 200ms).  
Black bar represents 34uM.   
 
Immunohistochemical stain on human fetal kidney sections acquired through an 
IRB-approved protocol of discarded specimens was performed using the same Ror2 
monoclonal antibody as described above.  Standard antigen unmasking procedures 
were used and protein was detected using di-amino benzidine.   
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CHAPTER 3 
 
ROR2, A DEVELOPMENTALLY REGULATED KINASE, PROMOTES TUMOR 
GROWTH POTENTIAL IN RENAL CELL CARCINOMA 
 
 
 
 
 
 
 
 
 
 
 
 
 
This work is modified from: Wright et al (2009) Oncogene (1) 
 
 
ABSTRACT 
Inappropriate kinase expression and subsequent promiscuous activity defines the 
transformation of many solid tumors including renal cell carcinoma (RCC).  Thus, the 
expression of novel tumor-associated kinases has the potential to dramatically 
shape tumor cell behavior.  Further, identifying tumor-associated kinases can lend 
insight into patterns of tumor growth and characteristics.  Here, we report the 
identification of Ror2, a new tumor-associated kinase in RCC cell lines and primary 
tumors.  Ror2 is an orphan receptor tyrosine kinase with physiological expression 
normally seen in the embryonic kidney.  However, in RCC, Ror2 expression 
correlated with expression of genes involved at the extracellular matrix, including 
Twist and matrix metalloprotease-2 (MMP2).  Expression of MMP2 in RCC cells was 
suppressed by Ror2 knockdown, placing Ror2 as a mediator of MMP2 regulation in 
RCC and a potential regulator of extracellular matrix remodeling.  The suppression 
of Ror2 not only inhibited cell migration, but also inhibited anchorage independent 
growth in soft agar and growth in an orthotopic xenograft model.  These findings 
suggest a novel pathway of tumor-promoting activity by Ror2 within a subset of renal 
carcinomas, with significant implications for unraveling the tumorigenesis of RCC. 
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INTRODUCTION 
Although tumor biology is tightly linked in many ways to the processes of 
embryonic development, a largely untapped area of solid tumor oncology is the 
specific examination of growth promoting pathways that are unique and critical to 
early developmental patterning.  One such signaling pathway, Wnt, is a process 
common to both developmental and malignant states (2).  The identification of these 
signaling molecules that play a physiologic role in early developmental processes, 
with potential to promote tumor growth or other pathologic characteristics in the 
adult, provides an opportunity to define biological cause for various tumor attributes 
(3).  Further, identifying such molecules with restricted tissue expression in the adult 
organism provides a valuable chance for diagnostic or therapeutic implementation. 
Epithelial cells require modulations in diverse signaling pathways to support 
the numerous cellular changes necessary to attain metastatic potential.  Specifically, 
receptor tyrosine kinase (RTK) activation causes deregulated signaling and can 
define tumor subsets across a broad spectrum of tumors (4).  Such variations in 
kinase activation have the potential to facilitate the cellular adaptations that 
determine patterns of tumor growth and can provide tremendous insight into the cell 
biology of that transformative process (5, 6).   
Among the cellular changes associated with tumor progression is tissue 
remodeling compatible with the extensive migration necessary for the progression of 
metastatic disease.  This cellular transition is shared by the developmentally 
regulated processes, which direct limb formation or other tissue patterning events.  
Tissue remodeling is driven by matrix metalloproteases (MMPs), a family of 
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enzymes that degrade the extracellular matrix (ECM), and is integral to both normal 
tissue development and cancer progression (7).  These processes signal cellular 
alterations that allow single cells to detach from the epithelial tumor collective, 
interrupting cell-cell junctions and increasing cell motility.  Taken together, this highly 
coordinated process is critical for the lethality of most epithelial malignancies.   
One such lethal epithelial malignancy, renal cell carcinoma (RCC), affects 
over 40,000 individuals in the US annually (8).  Nearly a third of these patients 
present with unresectable or metastatic disease, for which antiangiogenic therapies 
are the mainstay of therapy (9, 10).  RCC describes a group of histologically and 
genetically distinct neoplasms, the most common being clear cell RCC, with the 
remainder being papillary and chromophobe RCCs (11).  The mechanisms that 
promote tumor invasiveness or the acquisition of metastatic potential for the 
subtypes of RCC remain undefined. 
ECM remodeling, a common step towards invasiveness, is promoted by 
tumor cells through changes in intracellular signaling and commonly acquiring 
characteristics of less differentiated cellular precursors (7).  One developmentally-
regulated pathway inappropriately activated in many epithelial tumors is Wnt protein 
signaling via the frizzled and LRP co-receptors (12, 13).  Here we report the 
identification of a Wnt receptor of embryonic mesenchymal origin expressed in RCC 
cell lines and tumors that define a subgroup of human tumors with an invasive 
growth profile of gene expression. The novel receptor tyrosine kinase-like orphan 
receptor 2 (Ror2) is part of a family of orphan RTKs (14, 15).  Ror2 is characterized 
by an intracellular tyrosine kinase domain (16) and an extracellular Frizzled-like 
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cysteine-rich domain (CRD), shown to act as a receptor for Wnt ligands (17).  Mouse 
Ror2 (mRor2) expression is normally observed in the developing heart, brain and 
lungs (18-21), with the greatest expression seen in migrating neural crest and 
mesenchymal tissues (21).  In the developing kidney, we have observed Ror2 
expression in the migrating nests of mesenchymal cells.  Further, Ror2 expression 
was identified in RCC tumors and is coordinated with invasive growth in culture.  
Coupled with the observations that Ror2 impacts expression of MMP2 and tumor cell 
growth in vitro and in vivo, this study identifies a novel developmentally regulated 
receptor that enhances RCC tumor cell growth capabilities. 
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RESULTS 
Ror2 expression in RCC tumors defines a tumor genetic profile of ECM genes 
To analyze the role of Ror2 signaling in human RCC, an initial set of 13 
human tumors were examined for gene expression using the 44K Agilent array 
platform.  Tumors were classified as having undetectable, low, or high expression of 
Ror2 based on absolute Ror2 probe values on the array.  Ror2 expression on the 
array was congruent with expression patterns observed by conventional RT-PCR.  
Based on these designations, a three-way analysis for differentially expressed 
targets was performed.  When the 250 genes that associate most significantly with 
Ror2 expression (False Discovery Rate (FDR) < 0.07) were analyzed by hierarchical 
clustering, a subset of genes including extracellular matrix (ECM) candidates Twist1 
and Twist2 were identified (Figure 3.1).  In a larger, but still highly significant gene 
cluster for association with Ror2 (FDR < 0.15), the ECM factor MMP2 was also 
identified (Figure 3.1).  Other genes identified in this significant association included 
those linked with Wnt signaling such as catenin δ2, frizzled related protein and 
cathepsin K.    
 
 
 77
  
Figure 3.1: Microarray analysis defines a tumor genetic profile of ECM genes.  
Human RCC tumor microarray analysis.  Tumor mRNA was analyzed by Agilent 4x44K 
gene expression microarray and separated into groups with low (n=4), intermediate (n=5) or 
high (n=4) Ror2 expression.  SAM analysis was performed to identify differentially 
expressed genes, and the most significant (FDR <0.07) were analyzed by two-way 
hierarchical clustering, validating the observations in Figure 3 on an independent set of 
arrays.  
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In support of these data, additional RCC tumors were analyzed and clustered 
based on Ror2 expression.  Independent microarray analysis was performed using 
the same 44K Agilent array platform revealing a similar set of highly coordinately 
regulated genes which were identified in all RCC histologies with a FDR < 0.045 
(Figure 3.2A) and in clear cell with a FDR < 0.039 (Figure 3.2B).  Again, Twist1 and 
MMP2 were found to be tightly associated with Ror2 expression.  Altered expression 
for these transcripts (Twist1 and MMP2) was confirmed by quantitative RT-PCR of 
four representative tumors (two Ror2 + and two Ror2 -), confirming co-regulation 
(Figure 3.2C).  Gene set analysis further supports an association between Ror2 
expression and MMP2, identifying gene associations with the extended list of MMP 
family members and members of the Reck pathway.  Additionally, in its physiologic 
role, Ror2 is tightly linked to skeletal development, thus it is intriguing to see a gene 
set reminiscent of that process associated with high statistical significance with a 
subset of human tumors of epithelial origin.  An expanded listing of the members of 
the associated gene sets is shown in Figure 3.2D.  These gene sets validate the 
initial gene expression study and support a thematic program of gene expression in 
these tumors associated with extracellular matrix remodeling.  Together, these data 
extend a potential role for Ror2 as a mediator of tumor characteristics normally 
reserved for early and highly regulated developmental processes. 
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Figure 3.2: Microarray analysis of RCC tumors defines a tumor genetic phenotype.   
Tumor mRNA from 40 RCC tumors were analyzed by Agilent 4x44K gene expression 
microarray and separated into groups based on their Ror2 expression. SAM analysis was 
performed to identify differentially expressed genes, and the most significant in (A) all 
histologies (FDR <0.045) and (B) clear cell only histology (FDR<0.0388) were analyzed by 
two-way clustering.   
C.  Ror2 (+) RCC tumors have increased mRNA expression of genes involved at the ECM.  
Quantitative RT-PCR analysis of 2 Ror2 (-) and 2 Ror2 (+) human RCC tumors were 
analyzed to verify microarray expression.  Transcript values are normalized to β-actin RNA 
internal standard and are shown relative to an Ror2 (-) tumor (Tumor A).  Error bars 
represent SEM.  Significant differences were observed in Twist1 (*p<0.001) and MMP2 
(**p<0.0001) in the Ror2 (+) tumors (*p<0.001) compared to Ror2 (-) tumor (Tumor A), p-
values are based on cT values. 
D. Table showing the significant gene set list with corresponding genes involved at the ECM 
that clustered with Ror2 expression.  Tumor mRNA were analyzed by multiclass comparison 
using SAM, and the resulting Ror2 cluster was further analyzed for over-represented gene 
categories using the Expression Analysis Systematic Explorer (EASE) (22).  Genes from the 
three most tightly associated ontogenies are listed in the table. 
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Ror2 expression is significantly expressed in ccRCC tumors  
A statistical analysis of Ror2 gene expression as detected by a single 
randomly selected probe on a gene expression microarray demonstrates that Ror2 
expression is more highly expressed in tumors of clear cell histology than in papillary 
RCC tumors with high significance (Figure 3.3).  Also, those few tumors 
demonstrating chromophobe or mixed histology (data not shown) were not 
significantly distinct.  Overall, these data support Ror2 gene expression in human 
primary RCC tumors detectable in a high proportion of samples, particularly of the 
conventional clear cell type.   
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Figure 3.3:  Box plot of Ror2 transcript expression in RCC.  
Ror2 transcript expression comparing the primary histology of clear cell and papillary RCC 
tumors demonstrates a significantly higher expression of Ror2 among clear cell tumors 
compared to papillary RCC. 
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Ror2 expression directs MMP2 gene expression in RCC 
Based on the expression array findings, we sought to explore a direct 
relationship between Ror2 expression and the expression of genes involved in ECM 
remodeling.  Suppression of Ror2 protein in the 786-0 RCC cell line with two 
independent shRNAs targeting distinct regions of Ror2, in comparison to the 
scramble shRNA and control empty vector pRS, is demonstrated by immunoblot in 
Figure 3.4A.  The levels of Twist1 protein were also examined and no change in 
expression was observed by immunoblot analysis (Figure 3.4A).  This result 
suggests that Ror2 may be part of a larger program of gene expression but does not 
play a direct role in regulating Twist1 expression.  Ror2-deficient cells were 
examined by quantitative RT-PCR for effects on other genes expressed as a part of 
the ECM phenotype.  Transcript levels of MMP2 were highly suppressed by Ror2 
shRNA (Figure 3.4B).  Thus, Ror2 may participate in the coordinated events 
involved in renal epithelial ECM remodeling by regulating the expression of MMP2 in 
tumor cells derived from this tissue.  
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Figure 3.4: Ror2 expression directs MMP2 gene expression.   
A. Ror2 expression is suppressed in 786-0 cells by shRNA.  Whole cell protein extracts from 
RCC cells (786-0) were infected with a scramble short hairpin retrovirus, a pRS control virus 
or Ror2 short hairpin retroviruses and immunoblotted with polyclonal Ror2 antibody, Twist1 
antibody or Ku80 antibody as a loading control (LC).  
B. MMP2 expression is suppressed when Ror2 levels are knocked down.  Quantitative RT-
PCR analysis of two 786-0 Ror2 knockdown cell lines demonstrates MMP2 suppression 
coordinate with the degree of suppression of Ror2.  Significant differences were observed in 
MMP2 (**p<0.001 for both comparisons) in the 786-0 Ror2 suppressed cell lines compared 
to the Ror2 expressing cell lines (**p<0.001 for both comparisons).  Transcript values are 
normalized to β-actin RNA internal standard and are shown relative to 786-0 scramble RNA.  
Error bars represent SEM. 
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Ror2 expression directs cell migration and anchorage independent growth in RCC 
The functional consequence of Ror2 suppression was examined in assays of 
tumor cell invasive properties, beginning with cell migration.  Wound healing was 
measured as a means to quantify cellular migration because suppression of Ror2 by 
shRNA did not directly impact doubling time or viability of cultured cells (Figure 3.5).  
We examined wound healing in two independent stable shRNA Ror2 knockdowns 
generated in 786-0 subclones.  Healing was assayed in triplicate at 0, 8, 16, and 24 
hour timepoints.  Cells lacking Ror2 expression failed to close the wound as 
efficiently as their isogenic counterparts, scramble shRNA (data not shown) or pRS 
(Figure 3.6A), suggesting that Ror2 may play an important role in promoting cell 
migration. 
Another tumor cell characteristic of metastatic RCC and tumor invasiveness 
associated with the ECM is anchorage independent growth.  To determine whether 
Ror2 suppression also impacts this mode of cell growth, we assessed the growth of 
stable shRNA Ror2 knockdowns in soft agar (Figure 3.6B).  Colonies greater than 
150 uM in diameter were counted from triplicate plates in duplicate assays.  Cells 
lacking Ror2 expression retained the ability to survive as single cells in soft agar, but 
failed to proliferate.  These cells, therefore, failed to exhibit the anchorage 
independent growth of their Ror2-expressing isogenic counterparts, suggesting that 
Ror2 may play an important role in supporting cellular invasion in RCC 
tumorigenesis.   
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Figure 3.5: Ror2 suppression does not affect RCC cellular viability or doubling time.   
A.  Ror2 suppression does not inhibit RCC cell viability.  RCC cells (786-0) were infected 
with a scramble short hairpin RNA retrovirus, a control virus pRS or Ror2 short hairpin RNA 
retroviruses or a GFP control (without a selection marker).  Cells were plated on a 96-well 
plate and selected with puromycin for maintenance of the plasmid.  Cellular viability was 
examined via an MTT assay with comparisons made to uninfected/unselected 786-0 cells.  
There is no significant difference in cellular viability between the infected shRNA cell lines 
and the uninfected and unselected cell lines.  GFP infected cells confirm the selection 
activity.   
B. Ror2 knockdown does not change doubling time in 786-0 RC3 cells.  RCC cells (786-0 
RC3) were infected with a control virus pRS or Ror2 short hairpin RNA retroviruses, they 
were then plated and doubling time was observed over multiple passages.  No significant 
difference was observed in the doubling time of the control cell line as compared with the 
two independent shRor2 cell lines.   
 
0
0
0
0
0
0
0
786-0 scramble
786-0 pRS
786-0 shRor2.1 
786-0 shRor2.2
GFP 
A 
B 
y
 C
el
l V
ia
bi
lit
%
 
4  
8  
 
2  
6  
100 
12  
0 
5 
10 
15 
20 
25 
30 
D
ou
bl
in
g 
Ti
m
e 
786-0 RC3
pRS
786-0 RC3
shRor2.1
786-0 RC3
shRor2.2
 86
A 
pRS shRor2.1 shRor2.2 
 
 
 
Figure 3.6: Ror2 expression directs anchorage independent growth and invasive 
potential in vitro. 
A. Ror2 knockdown decreases cell migration.  RCC cells (786-0) infected with a control virus 
pRS or Ror2 short hairpin RNA retroviruses were plated and allowed to grow overnight. 
Cells were scratched and the length of the scratch was observed for both 0 hr and 16hr 
timepoints (left).  Significant differences were observed when comparing the % invasion of 
the Ror2 knockdown cell lines compared to the empty vector pRS control (right) - 
(**p<0.0001, *p=0.009).  Error bars represent SEM. 
B. Ror2 knockdown inhibits anchorage independent growth.  RCC cells (786-0) infected with 
a scramble short hairpin RNA retrovirus, a control virus pRS or Ror2 short hairpin RNA 
retroviruses were allowed to grow in soft agar over a period of 3-4 weeks. Ror2 knockdown 
cells have inhibited growth in comparison to the scramble short hairpin retrovirus and the 
empty vector pRS control.  Multicellular colonies >150 uM were counted from triplicate 
plates.  Data shown is from the combination of two representative experiments (**p<0.0001).  
Error bars represent SEM.  Inset - Cells were stained with MTT dye, and pictures taken at 
10x magnification.  Black bar represents 67.3 um. 
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Ror2 overexpression enhances anchorage independent growth  
As Ror2 suppression is shown to be necessary for anchorage independent 
growth, we also asked if Ror2 expression was sufficient to induce growth.  Human 
Ror2 (hRor2) expression plasmids were generated for expression in two RCC cell 
lines – 786-0 where Ror2 is highly expressed (Figure 3.7A) and a derivative line, 
WT8, where Ror2 expression is negligible (Figure 3.7B).  Adding more hRor2 to the 
786-0 cell line did not change anchorage independent growth (Figure 3.7C) 
suggesting that increasing the level of Ror2 beyond a threshold fails to impact this 
feature of tumorigenicity.  However, when hRor2 was added to an RCC cell line that 
lacks robust Ror2 expression, an increase in anchorage independent growth was 
observed (Figure 3.7D), suggesting that Ror2 is sufficient to enhance anchorage 
independent growth.  Taken together, these data suggest that Ror2 expression is 
sufficient for the anchorage independent growth characteristic of RCC.   
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Figure 3.7: Ror2 overexpression enhances anchorage independent growth in vitro.   
A. Ror2 expression is increased in 786-0 cells with an overexpression plasmid.  RCC cells 
(786-0) were transfected with control plasmid pcDNA6 or hRor2 cDNA and immunoblotted 
with polyclonal Ror2 antibody, a V5 antibody or Ku80 antibody as a loading control (LC).  
B. Ror2 expression is amplified in the 786-0 derivative cell line WT8, a clone expressing a 
VHL cDNA which expresses reduced levels of Ror2.  The RCC cell line WT8 was 
transfected with a control plasmid pcDNA6 or hRor2 cDNA and immunoblotted with 
polyclonal Ror2 antibody, a V5 antibody or Ku80 antibody as a loading control (LC).  
Panel A and B represent a contiguous blot with intervening lanes removed. 
C. An increase in Ror2 expression in Ror2 expressing cells does not affect anchorage 
independent growth.  RCC cells with high levels of Ror2 already expressed (786-0) 
transfected with a control plasmid pcDNA6 or hRor2 cDNA were allowed to grow in soft agar 
over a period of 3-4 weeks.  Multicellular colonies >150 uM were counted from triplicate 
plates.  An increase in Ror2 expression did not change colony growth.  Data shown is from 
two representative experiments.    
D.  Ror2 overexpression increases anchorage independent growth in cells lacking Ror2 
expression.  RCC cells lacking high level of expression of Ror2 (WT8) transfected with a 
control plasmid pcDNA6 or hRor2 cDNA were allowed to grow in soft agar over a period of 
3-4 weeks. Multicellular colonies >150 uM were counted from triplicate plates.  Ror2 
overexpression cells displayed enhanced growth in comparison to the control empty vector 
pcDNA6. Data shown is from one representative experiment (p=0.079). 
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Ror2 suppression reduces tumor growth in vivo   
As our data showed that 786-0 Ror2 shRNA suppressed anchorage 
independent growth in vitro in RCC cells, we also sought to assess tumor growth in 
vivo.  Two independently derived Ror2 deficient cell lines and an isogenic control 
shRNA cell line were injected orthotopically in a cohort of athymic nude (nu/nu) 
female mice.  Macroscopically visible tumors were only detected in mice injected 
with 786-0 isogenic control cells.  Additionally, the control cell line had significantly 
more tumors than the two shRNA cell lines combined.  The histology of a control 
engrafted tumor with adjacent normal kidney tissue is shown in Figure 3.8A.  By 
comparison, tumor cells derived from the Ror2 suppressed cells were present on 
microscopic evaluation of two kidneys in the vicinity of the kidney subcapsule (Figure 
3.8B, arrows), but failed to form clearly discrete masses.  The extent of tumor 
growth, including tumors which implanted outside the area of injection, is quantified 
in the panel of Figure 3.8C and the average of all ten implants (in cm) was larger in 
the isogenic control cell line than in the two shRNA cell lines (Figure 3.8D).  This 
experiment was replicated independently with xenografts grown longer than 3 
months, and the results mirrored these findings (data not shown).  MMP2 protein 
levels were also examined in these engrafted tumors.  As previously shown at the 
transcription level, when Ror2 is expressed there is an abundance of MMP2 protein 
expression (Figure 3.8E, F).  In tumors where Ror2 expression is suppressed, 
MMP2 protein levels are decreased (Figure 3.8G, H).  This data confirms in vivo the 
findings of the experiments examining anchorage independent growth, validating a 
role for Ror2 in promoting tumor cell growth independent of tumor cell survival in 
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RCC.  Further, this data provides concrete evidence that, for the first time, links Ror2 
to RCC tumor development and places this signaling pathway as an immediate 
facilitator of tumor growth.   
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Figure 3.8: Ror2 suppression reduces tumor growth in vivo.  
Two independent shRNA cell lines were injected orthotopically under the kidney capsule of 
athymic nude mice, compared to 786-0 pRS control cells.   
A. Histology of control engrafted tumor with adjacent normal kidney tissue is shown.  
B. H&E of the kidney surface demonstrated that Ror2-suppressed engrafted tumor cells 
were present in the vicinity of the subcapsule microscopically but failed to form distinct 
tumors.  
C.  Macroscopically visible tumors were only detected in mice injected with 786-0 pRS 
control cells.  Macroscopic and microscopic evidence of tumor cells was tabulated, 
demonstrating significantly more tumors identified in the control cell implanted mice than 
those implanted with either of the two Ror2 shRNA cell lines.  
D. Average tumor diameter of each implant from the 786-0 pRS control cell line and the two 
Ror2 shRNA cell lines (in cm).   
E. The control engrafted tumor, 786-0 pRS, displays increased levels of MMP2 as 
determined by immunohistochemistry.  
F.  Control panel for 786-0 pRS shows negative staining in the no primary control.   
G. The Ror2-suppressed engrafted tumor, 786-0 shRor2.1, has diminished levels of MMP2 
expression compared to the empty vector control, 786-0 pRS.   
H. Control panel for 786-0 shRor2.1 shows insignificant background staining in the no 
primary control.   
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DISCUSSION 
In a strategy to uncover potential signaling kinases for RCC, we have 
identified the developmentally regulated orphan kinase Ror2 as an activated tyrosine 
kinase in RCC cancer cell lines and renal tumors.  Ror2 is physiologically expressed 
primarily on embryonic mesenchymal cells and developmentally expressed on 
migrating mesenchymal cells of the fetal kidney.  The aberrant expression of Ror2 in 
human RCC tumors has not been specifically described to date, although evidence 
of active Ror2 has been observed on kinase arrays from glioblastoma cell lines (4).  
In this study, however, for the first time we show that Ror2 expression was detected 
in the majority of human RCC tumors, and protein expression was confirmed at the 
tumor cell level.  These data support the identification of a tumor cell intrinsic 
receptor tyrosine kinase, usually limited to developing mesenchymal cell subsets, 
that is detectable on the majority of renal cell carcinomas. 
Ror2 expression in RCC may herald the activation of many signalling events, 
particularly in the aberrant context of a tumor cell environment.  For epithelial cells to 
metastasize, they must acquire mesenchymal characteristics that permit proliferation 
outside of the usual niche.  Ror2 is primarily expressed in mesenchymal cells, 
immediately suggesting a possible role for this kinase as part of the ECM remodeling 
process in tumor development.  Expression of the Ror2 kinase in human tumors was 
found to be tightly correlated with genes involved at the ECM, in particular MMP2, 
linking this epithelially derived tumor with mesenchymal phenotypic markers and a 
potentially important transitioning event in the development of invasive renal cell 
carcinoma.  Matrix metalloprotease-2 (MMP2) has previously been shown to be 
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overexpressed in many metastatic cancers including RCC (23, 24) and Ror2 may 
define an important and unique pathway for this process in kidney cancers (23).  
MMP2, in particular among the MMP family, is essential for the renal tubular cell 
epithelial to mesenchymal transformation (EMT) specific to the recovery from renal 
tubular injury (25).  This process requires adaptations of the extracellular matrix as 
well as mechanisms of promoting cellular migration.  Using wound healing as a 
surrogate for cell migration, we found that Ror2-suppressed cells migrated at a 
slower rate than their isogenic partners.  As a critical test of tumor cell growth in a 
three-dimensional environment, Ror2 expression supported anchorage independent 
cell growth, an indicator of tumor cell growth and a critical quality of metastatic 
tumors.  We further demonstrated that suppression of Ror2 was sufficient to inhibit 
tumor growth in xenografts, suggesting a key role in permitting the 3-dimensional 
growth essential for tumor formation.   
It is additionally intriguing to consider the unique embryonic origins of the 
kidney, in which the epithelial tissues are entirely derived from a mesenchymal 
source.  The process of developing the excretory tubules has in fact been termed a 
“mesenchymal to epithelial transition” (26).  The kidney is derived from the ureteric 
bud and the metanephric mesoderm (27), thus the emergence of Ror2 as a part of a 
dedifferentiation profile may provide the embryonic signal necessary to reinact a 
mesenchymal program in malignant epithelial cells derived from the kidney.  Taken 
together, these data suggest that Ror2 can play an important role in renal cell 
carcinoma growth patterns by providing tumor cells with an immature phenotype 
primed for invasive growth.   
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Further, the regulation of Wnt signaling via Wnt receptors such as Ror2 can 
be greatly influenced by the availability of Wnt ligands, Frizzled family members, and 
factors such as the secreted frizzled related protein 1, which may influence the 
activity of Ror2 in tumorigenicity (28).  It remains uncertain which specific Wnt 
signaling pathway Ror2 engages as a cancer promoting factor; thus, the 
identification of Ror2 as a feature of RCC presents a novel avenue for future 
integrated studies of developmental and cancer biology.   
Ror2 activity thus defines a novel component of the signaling machinery in 
place to promote the growth of many renal tumors and may define a unique tumor 
subset with distinct pathologic or physiologic characteristics.  Finally, this newly 
identified kinase in RCC provides an ideal candidate to explore as a marker of 
tumors with aggressive growth potential or as a putative target to disable tumor 
growth. 
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MATERIALS AND METHODS 
Cell Culture 
786-0 and RCC4 cell lines and their derivatives, including the paired cell lines 786-0 
WT8 and 786-0 RC3 (kindly provided by Dr. W. Kaelin, Boston, MA), RCC4 2-1 and 
RCC4 3-14 (kindly provided by Dr. M.C. Simon and Dr. B. Keith, Philadelphia, PA), 
were maintained in Dulbecco’s Modified Eagle Medium (DMEM) with 10% fetal 
bovine serum (FBS), L-glutamine and non essential amino acids.  The shRNA 
knockdown cells were generated by infecting the cells with commercial shRNAs for 
Ror2 (Origene Technologies Inc, Rockville, MD).  Two shRNAs targeting separate 
portions of the gene were used in these studies.  Selection to maintain the shRNA 
was achieved with puromycin supplementation of the media for these cells. Cell lines 
overexpressing Ror2 were generated by transferring hRor2 cDNA (Origene 
Technologies Inc, Rockville, MD) into the pcDNA6/V5-HisA plasmid (Invitrogen, 
Carlsbad, CA) via SacI/XhoI restriction enzyme sites (New England BioLabs Inc, 
Ipswich, MA).  The HKC line (kindly provided by Dr. L. Racusen, Baltimore, MD (29)) 
was maintained in DMEM/F12 supplemented with 10% FBS.   
  
Immunoblotting 
Cells were lysed in whole cell extraction buffer containing 20mM Tris, 100mM NaCl, 
1 mM EDTA, 1% NP-40 and protease inhibitor cocktail (Roche Diagnostics, 
Indianapolis, IN).  Bradford reagent was used to assess the concentration.  Protein 
samples were separated on 8% SDS-polyacrylamide gels and transferred to 
nitrocellulose (GE, Pittsburg, PA).  The following antibodies were used to assess for 
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expression: Monoclonal Ror2 at 1:250 (RND Systems, Minneapolis, MN), Polyclonal 
Ror2 at 1:3000 (RND Systems, Minneapolis, MN), Twist1 at 1:1000 (Cell Signaling 
Technology Inc, Danvers, MA), V5-HRP at 1:2500 (Invitrogen, Carlsbad, CA) and 
Ku80 at 1:2000 (Genetex Inc, San Antonio, TX) as a loading control (LC).  
Appropriate horseradish peroxidase conjugated secondary antibodies were used 
and proteins detected using ECL-Plus chemiluminescence reagents (GE, Pittsburg, 
PA).   
 
Wound Healing Assay 
35,000 cells were plated in triplicate on 6-well plates and allowed to adhere 
overnight at 37°C in 10% FBS containing RCC media.  The monolayer was then 
“wounded” in perpendicular directions with a 200ul pipet tip (forming a cross) and 
2% FBS containing RCC media was added.  Pictures were taken at each of the 
cross section junctions at 4x magnification at 0, 8, 16, and 24 hours.   
 
Soft Agar Colony Formation Assay 
0.6% bottom agar was plated onto 6-well plates.  10,000 cells were then plated in 
triplicate, placed at 37°C overnight and covered with 0.2mL RCC media.  Colonies 
were allowed to form over 3-4 weeks and then stained with 2mg/mL MTT (Sigma-
Aldrich, St. Louis, MO) for 1-4hrs.  Images were taken at 10x magnification.  Black 
bar represents 67.3μm.   
 
Cell Viability Assay 
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A modified MTT assay (Promega, Madison, WI) was used to assess cell viability.  
5,000 cells were plated with 50uL selection media for 5 days.  The MTT dye 
containing the tetrazolium salt was added according to manufacturer instructions 
and absorbance measured at 570nm. 
 
Doubling Time Assay 
300,000 cells were plated and after 96hrs, the total number of cells was counted.  
This process was repeated 10 times and the doubling time calculated.  
 
qRT-PCR Analysis  
Total RNA was prepared from 80% confluent plates using Gentra Systems RNA 
Extraction Cell Kit (Minneapolis, MN).  cDNA was made from 0.5µg total RNA by 
reverse transcriptase (RT) using oligo dT primers and the Superscript II RT-PCR 
reagents (Invitrogen, Carlsbad, CA).  For automated TaqMan qRT-PCR, proprietary 
commercial FAM labeled primers were used targeting Ror2, MMP2, Twist1 and β-
actin (Applied Biosystems, Foster City, CA) and analyzed on the 7900H Fast Real-
Time PCR System (Applied Biosystems, Foster City, CA). 
 
Microarray Analysis 
Fresh frozen tumors from the UNC Tissue Procurement Facility tumor bank (1994-
2007) were used for these studies.  Total mRNA was prepared as described above, 
incorporating a Rotor-Stator for tissue homogenization and quantified with the 
NanoDrop (NanoDrop Technologies, Wilmington, DE).  RNA quality check, 
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amplification, labeling, and hybridization were performed by the UNC Genomics 
Core Facility.  Two-color hybridization was performed, with a modified reference 
human mRNA derived from the Stratagene Universal Human Tumor Reference RNA 
(kindly provided by Dr. C. Perou, University of North Carolina at Chapel Hill) and 
compared to each tumor. 
 
Raw data was derived using Agilent feature extraction software, and results were 
expressed as a Log (2)-transformed ratio between tumor and control mRNA. Three-
way comparison was performed using Significance Analysis of Microarrays (SAM) 
version 3.01 (30) for Figure 3.1.  The 250 most significantly altered genes were then 
used for clustering analysis. After duplicate genes were removed, targets were 
median centered and complete linkage analysis was performed with Pearson’s 
Correlation with Cluster 3.0.  For Figure 3.2, quantitative analysis of data according 
to Ror2 gene expression was performed using SAM.  Genes with a false discovery 
rate <5% were then used for average linkage analysis with Cluster 3.0. Gene set 
analysis was also performed in SAM according to Ror2 gene expression values, 
using a cutoff of FDR=0. Gene sets analyzed were from Erin Segal or the MSigDB 
collection at the Broad Institute. 
 
Xenograft Analysis 
500,000 cells were injected orthotopically under the kidney capsule in a cohort of 
athymic nude (nu/nu) female mice and aged 2.5 or 3 months.  The xenografted 
tumors were formalin fixed, paraffin embedded and tissue blocks were serially 
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sectioned onto unprepared glass slides.   Xenografted tumors were stained with 
hematoxylin and eosin (H&E) for tumor verification.  The slides were immunostained 
with MMP2 antibody 3158 (Abcam Inc, Cambridge, MA) and detected as previously 
described in Chapter 2.  
 
Statistical Analysis 
The standardized cT values were fit with a one-way ANOVA model with the 
experimental variable of interest (Ror2, etc) as the fixed effect.  To verify the one-
way ANOVA model, a nonparametric statistical procedure, Kruskal-Wallis test, was 
performed to compare the standardized cT among the cell lines.  Error bars are 
shown as standard error of the mean.   
 
Ror2 expression was evaluated across RCC tumor histologies using a Student’s T 
test to assign the p-value as shown.  Because clear cell tumors are more common 
than other histologies, the difference in sample size is reflected in the standard 
deviations using an adjustment to account for unequal variances.   A non-parametric 
Wilcoxon Rank Sum procedure was performed to confirm the significant result found 
using the parametric two sample t-test.   
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CHAPTER 4 
 
IDENTIFICATION OF ROR2 AS A HYPOXIA INDUCIBLE FACTOR (HIF) TARGET 
IN VON HIPPEL-LINDAU (VHL) ASSOCIATED RENAL CELL CARCINOMA 
 
 
 
 
 
 
 
 
 
 
 
 
This work is modified from: Wright and Rathmell (2010), Journal of Biological 
Chemistry (1) 
 
 
ABSTRACT  
Ror2 is an orphan receptor tyrosine kinase with expression normally restricted to 
early stages of development.  However, emerging evidence has placed aberrantly 
expressed Ror2, leading to an invasive phenotype, in several cancers including 
renal cell carinoma (RCC).  Though Ror2 is currently identified as upregulated in an 
assortment of cancers, neither the regulatory role or mechanism of action have been 
delineated.  We sought to place Ror2 in RCC’s most commonly mutated pathway, 
the loss of the tumor suppressor von Hippel-Lindau, VHL, which causes hypoxia 
induced factor (HIF)-1α and 2α stabilization and the transcriptional activation of a 
broad repertoire of response genes.  We found that Ror2 was indeed associated 
with pVHL loss in RCC as well as with VHL somatic mutations tightly coordinated 
with the induction of RCC.  Additionally, knockdown and rescue analysis of HIF 
expression suggests that Ror2 is dependent on the pathologic stabilization of either 
HIF-1α or HIF-2α.  Subsequent evaluation of the Ror2 promoter suggests that HIF-
2 and its dimerization partner, aryl hydrocarbon nuclear transferase, ARNT, 
localize to the Ror2 promoter via a cryptic transcriptional element.  This data 
substantiates a unique regulation pattern for Ror2 in the VHL-HIF axis that has the 
potential to be applied to other cancer etiologies.   
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INTRODUCTION 
The tyrosine kinase Ror2 was initially identified as a homologue of the Trk 
neurotrophin receptors (2) and later as a member of the receptor tyrosine kinase 
superfamily (3).  Ror2 is an orphan receptor with expression in the developing 
embryo identified in the embryonic limb buds, heart, primitive genitalia, developing 
somites, and mesenchymal cells in the developing lung, kidney, and cephalic 
regions (4-6).  In the adult organism, Ror2 expression is present as a part of 
osteoblast differentiation, highly induced in the preosteoblast stage (7), and is 
suppressed as these cells terminally differentiate as osteocytes.  This pattern of 
expression is inversely related to that of secreted frizzled related protein 1 (sFRP1), 
and can be transcriptionally suppressed by ectopic expression of sFRP1 in this cell 
type, but further insights into the major elements of Ror2 regulation are not known.   
Aside from developmental programs regulating bone morphogenesis and 
primitive organ development, Ror2 has only recently been recognized to play a role 
in the adult organism.  We have identified Ror2 expression as a characteristic of 
many renal cell carcinoma (RCC) cell lines and human tumors (8), where its 
expression is associated with increased cell migration and anchorage independent 
growth.  Ror2 also plays a prominent role in osteosarcoma (9) and has recently been 
identified in squamous cell carcinoma of the head and neck, where expression 
parallels the development of invasive features of these tumors (10).  Further, in a 
tumor genomic analysis of invasive gastric cancers, Ror2 was identified as a 
frequent target of mutagenesis (11).  These findings place Ror2 as a frequently 
upregulated feature of human cancers, and in each case, is associated with invasive 
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tumor characteristics.  Though Ror2 has been identified as a frequently 
overexpressed protein in a variety of tumor types, what regulatory or mechanistic 
events contributing to increased Ror2 expression in these tumors have yet to be 
deduced.   
Ror2 was initially identified as a renal tumor antigen in cell lines derived from 
clear cell renal cell carcinomas which were known to have inactivating mutations of 
the von Hippel-Lindau (VHL) tumor suppressor.  The majority of clear cell RCC 
tumors are characterized by mutation, methylation, or loss of the VHL gene (12-15).  
The most well-documented function of the pVHL protein is to act as the substrate 
recognition component of an E3 ubiquitin ligase complex which includes Elongin C, 
Elongin B, Cullin 2, and ring box protein 1 (Rbx1 or Roc1) (16-19).  The substrates 
of pVHL E3 ligase activity most tightly associated with RCC are the hypoxia 
inducible factor (HIF)-α subunits (HIF-1α and HIF-2α), a family of transcription 
factors which coordinate much of the physiologic response to restricted oxygen 
availability (20-23).  Under normal oxygen conditions, the prolyl hydroxylases 
(PHDs) hydroxylate the HIF subunits which are subsequently recruited by pVHL to 
an E3 ubiquitin ligase complex for ubiquitylation, leading to proteasomal degradation 
(24-26).  Under low oxygen conditions or as a result of VHL inactivation, one or both 
of these HIF factors are stabilized leading to the formation of a transcriptional 
complex with aryl hydrocarbon receptor nuclear translocator (ARNT, also known as 
HIF-1), inducing the transcription of a large panel of hypoxia responsive genes 
including vascular endothelial growth factor (VEGF), glucose transporter 1 (Glut1), 
prolyl hydroxylase family member Egln3 (also known as PHD3), among many others 
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(27, 28).  This transcriptional response leads to the highly vascular phenotype of 
RCC and the transformed phenotype of the cells (29).   
VHL mutation is an important event in the development of RCC, and 
activation of components of the HIF pathway can be detected early in pre-malignant 
cysts that precede the development of cancer in patients harboring a germline 
mutation in VHL (30).  However, within the spectrum of VHL mutation, tumors can 
demonstrate either stabilization of one or both these HIF factors, and may promote 
the transcriptional activation of certain subsets of the repertoire of hypoxia response 
induced genes (28).  Additionally, the VHL mutational subtype may itself mediate 
HIF expression patterns based on studies in vitro (31), which parallel tumor growth 
in vivo (32).   In particular, examination of human RCC tumors has demonstrated 
that the molecular profile of tumors is highly dependent on the expression of HIF1 
and HIF2 in comparison to those tumors solely expressing HIF2, with distinctions 
which correlate with divergent tumor activity (33).   
Though VHL mutation and HIF dysregulation have been identified as major 
contributors to the RCC tumor phenotype, the specific molecular mechanisms 
associated with this pathway that contribute to RCC features of cell growth, invasion 
or metastasis remain an active area of investigation.  Thus, we sought to examine 
the potential that Ror2 regulation was occurring as a part of the VHL/HIF axis in 
RCC.  We found that Ror2 expression was definitively associated with the loss of 
pVHL as well as with VHL mutations most tightly correlated with HIF-2α 
dysregulation.  Knockdown analysis and rescue experiments suggest that Ror2 is 
dependent on the pathologic stabilization of either HIF-2α or HIF-1α expression, 
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although it is not expressed as a component of the physiologic response to hypoxia.  
This finding prompted an examination of the Ror2 promoter, which suggests that 
HIF-2α and ARNT are localized to the Ror2 promoter, potentially utilizing a cryptic 
element for its interaction.  Coupled with observations that Ror2 has been shown to 
be involved in the invasive tumor phenotype of RCC and other malignancies, this 
study places Ror2 in the VHL–associated HIF transcriptional pathway associated 
with VHL mutation-mediated stabilization of HIF factors providing support for a 
model where the spectrum of HIF target genes activated as a result of VHL mutation 
may contribute substantially to the phenotype of an individual tumor.   
 112
RESULTS 
Ror2 expression in clear cell RCC is dependent on VHL status 
Our previous work has shown that Ror2 is expressed in RCC tumors and 
RCC cell lines.  However, the tumorigenic mechanism that contributes to this 
aberrant regulation of Ror2 in RCC remained uncertain.  Since pVHL expression is 
tightly associated with clear cell RCC, and the RCC cell lines in which Ror2 was 
initially identified lack functional pVHL expression, we sought to evaluate the 
expression of Ror2 in RCC cell lines in relation to pVHL status.  Whole cell extracts 
were examined by immunoblot for Ror2 expression in two independent sets of RCC 
cell lines.  Ror2 was first examined in the VHL mutant cell line 786-0, stably 
transfected with empty expression vector (786-0 RC3), confirming Ror2 protein 
expression demonstrated by two independent antibodies targeting the Ror2 
extracellular domain.  However, when pVHL expression was restored by the addition 
of a HA-tagged VHL cDNA (786-0 WT8), Ror2 expression was undetectable using 
either antibody (Figure 4.1A).  To explore the nature of this regulation as a 
transcriptional event or as a consequence of protein stabilization, the VHL-
dependent expression of Ror2 in RCC was assayed at the mRNA level using qRT-
PCR.  The VHL (-) 786-0 RC3 vector control cell line had significantly enhanced 
Ror2 expression of transcript compared to the VHL (+) wildtype 786-0 WT8 
derivative cell line, for which no transcript was detectable (Figure 4.1B), paralleling 
the protein levels.   
To verify that the VHL dependent regulation of Ror2 observed was not cell 
line specific, we utilized the RCC4 paired cell line for further analysis.  Our results 
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showed that VHL-null RCC4 cells stably transfected with vector (RCC4 2-1) 
expressed Ror2, whereas RCC4 cells stably expressing an HA-tagged wild type 
VHL cDNA (RCC4 3-14) displayed dramatically reduced levels of Ror2 protein as 
detected by immunoblot (Figure 4.1C).  This VHL dependency was also confirmed at 
the transcript level as Ror2 mRNA was suppressed to a significant degree in the 
VHL (+) cell line RCC4 3-14 compared to the VHL (-) counterpart RCC4 2-1 (Figure 
4.1D).  These findings confirm that Ror2 expression is VHL-dependent at both the 
protein and mRNA levels suggesting a transcriptionally regulated mechanism of 
Ror2 expression is involved in multiple RCC cell lines.  
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Figure 4.1: Ror2 is regulated by VHL status.   
A. Ror2 is expressed when VHL is mutated in the 786-0 paired cell line. Whole cell extracts 
from 786-0 cells expressing (786-0 WT8) or lacking expression (786-0 RC3) of pVHL were 
immunoblotted with monoclonal Ror2 antibody - Ror2 (1), polyclonal Ror2 antibody - Ror2 
(2) and Ku80 antibody as a loading control (LC).    
B. Ror2 expression is regulated at the transcriptional level in the paired 786-0 cell lines.  
qRT-PCR analysis data is normalized to β-actin as an RNA internal standard and displayed 
as expression levels relative to the pVHL expressing member of the cell line pair.  
Significant differences were observed as Ror2 mRNA levels were suppressed in the VHL (+) 
cell line (light gray), relative to the paired vector transfected VHL (-) control (dark gray), 
**p<0.0001.  
C. Ror2 is expressed when VHL is mutated in the RCC4 paired cell line.  Whole cell extracts 
from RCC4 cells expressing (RCC4 3-14) or lacking expression (RCC4 2-1) of pVHL were 
immunoblotted with monoclonal Ror2 antibody - Ror2 (1), polyclonal Ror2 antibody - Ror2 
(2) and Ku80 antibody as a loading control (LC).  
D. Ror2 expression is regulated at the transcriptional level in the paired RCC4 cell lines.  
qRT-PCR analysis data is normalized to β-actin as an RNA internal standard and displayed 
as expression levels relative to the pVHL expressing member of the cell line pair.  
Significant differences were observed as Ror2 mRNA levels were suppressed in the VHL (+) 
cell line (light gray), relative to the paired vector transfected VHL (-) control (dark gray), 
**p=0.0001.  
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As regulation of Ror2 by wild type pVHL protein was evident at both the 
protein and mRNA levels, we also sought to evaluate the expression of Ror2 using 
the tight genotype/phenotype correlation seen with representative VHL mutations 
associated with the various VHL disease subtypes.  We examined a panel of VHL 
somatic point mutants expressed in 786-0 cells, representative of the mutant VHL 
transgenes seen in the major subtypes of VHL disease associated with cancer 
predisposition.  VHL Type 2B mutations are associated with the most diverse 
presentation of VHL disease and are thought to be more highly penetrant for the 
development of RCC.  In these stable clonal cell lines expressing representative 
pVHL proteins, overexpression of Ror2 was detected by immunoblot only in the 
absence of pVHL or in the presence of a representative mutant pVHL of VHL 
disease, subtype Type 2B (Figure 4.2). This mutation, arginine 167 to glutamine 
(R167Q), has previously been associated with HIF-2α stabilization similar in extent 
to the VHL (-) cells (31).  Further, representative mutations of VHL disease subtypes 
2A, which displays minimal deregulation of HIF factors and low risk for renal cell 
carcinoma and Type 2C, which retains complete regulation of HIF factors and 
produces no risk for renal cell carcinoma, were completely able to reverse the 
aberrent Ror2 expression.  This data ties the expression of Ror2 VHL mutation, and 
to correlative genotype/phenotype VHL regulation and its expression in RCC.        
 116
VHL Subtype     1 2A 2B 2C 
Mutation     ST      R167 Y112H Q       L188V 
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Figure 4.2: Expression of Ror2 in VHL somatic mutation subtypes.   
A panel of VHL point mutant transgenes expressed in 786-0 cells, which recapitulate the 
mutant VHL genes representative of the major subtypes of VHL disease, was subjected to 
immunoblot analysis.  There is graded HIF-2α expression associated with the VHL 
mutations, with the greatest HIF-2α levels present in the cells expressing the VHL type 2B 
mutant and the vector transfected cells which lack pVHL expression.  Expression of Ror2 is 
permitted only in the most penetrant subtype, VHL Type 2B.  
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Minimal induction of Ror2 under hypoxic conditions   
The findings that Ror2 expression was associated with VHL loss or mutations 
associated with HIF deregulation suggested that Ror2 expression was correlated 
with HIF-2α stabilization.  Thus, we asked if Ror2 might be regulated by the cellular 
hypoxic response.  Multiple strategies were evaluated as stimulants of Ror2 
expression, beginning with prolonged exposure to 1% hypoxia.  786-0 and RCC4 
derived cells were exposed to 1% oxygen over a 16 hour period of induction.  HIF 
levels were elevated at baseline in the vector transfected control VHL mutant cell 
lines, and further induction with hypoxia was not observed.  As expected, physiologic 
stabilization of HIF-2α in response to hypoxia was observed by immunoblot in each 
of the pair of cell lines expressing functional pVHL.  At the protein level, no 
discernable change in Ror2 was observed, in contrast to induction of the established 
hypoxia target Glut1 (glucose transporter-1) - Figure 4.3A.  We further examined 
Ror2 as a target of the hypoxic response by evaluating Ror2 protein levels in the 
paired 786-0 RCC cells after 48 hours of stimulation with cobalt chloride (CoCl2), a 
potent hypoxia mimetic.  Again, in contrast to the effect on HIF-2α levels, which were 
induced as predicted in those cells expressing wild type pVHL, Ror2 protein levels 
were at most only minimally induced in the cell lines with functional VHL in contrast 
to the vivid induction seen with the established hypoxia target Egln3.  CoCl2 
treatment did not further induce expression levels in the cell line lacking functional 
VHL (Figure 4.3B).  Additional studies extending the period of hypoxic induction out 
to 72 or 96 hours failed to induce Ror2 levels farther (data not shown).   
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As the primary event of hypoxia response signaling occurs at the 
transcriptional level, effects of chemical induction of the hypoxia response were 
examined using quantitative RT-PCR.  We again examined the effect of CoCl2 
treatment on activation of Ror2 and the hypoxia response.  The HIF target transcript 
Egln3 (a HIF dependent prolyl hydroxylase) served as an additional control to Glut1 
to demonstrate the effect of these treatments on hypoxia response gene induction.  
In response to CoCl2 treatment, we observed an appropriate and significant increase 
in Egln3 mRNA after 24 hours.  However, no significant change was observed in the 
levels of Ror2 transcript in response to this treatment (Figure 4.3C, left).  A second, 
more potent, chemical mimetic of hypoxia, the prolyl hydroxylase inhibitor 
dimethyloxalylglycine (DMOG), was tested to determine if maximal induction of this 
pathway may be sufficient to generate an induction in Ror2 levels after 24 hours of 
treatment.  Both control transcripts (Glut1 and Egln3) were robustly induced in 
response to this treatment within the 786-0 WT8 cell line (with functional VHL) 
demonstrating a functional hypoxia pattern of transcriptional response.  Again, the 
more potent hypoxia mimic, DMOG, also failed to show a statistically significant 
increase in total Ror2 transcript levels (Figure 4.3C, right).  Therefore, although VHL 
inactivation is associated with the dysregulated expression of Ror2, activation of the 
hypoxia response by either potent chemical inducers or profound exposure to low 
oxygen levels were not sufficient to engage the transcript or protein expression of 
Ror2. 
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Figure 4.3: Minimal hypoxia induction of Ror2 expression.   
A. Ror2 expression is minimally induced under 1% hypoxic (H) conditions.  Whole cell 
extracts from 16 hour normoxic (ambient oxygen, N), and hypoxic (1% oxygen, H), treated 
cell cultures were immunoblotted for HIF-2α, Ror2, Glut1, and Ku80 as a loading control 
(LC).  HIF-2α and Glut1 induction is expected due to protein stabilization under conditions of 
hypoxia in cells expressing VHL and confirms the exposure of cultures to the hypoxic 
condition but minimal change in the Ror2 protein level is detected.   
B. Ror2 expression is minimally induced after 48 hours of exposure to cobalt chloride (C).  
Normoxic (N) and cobalt chloride, CoCl2, treated (C) protein samples were immunoblotted 
with HIF-2α antibody to show that HIF-2α was induced in the VHL (+) cell lines.  However, 
Ror2 levels remained stable to this manipulation.  Ku80 antibody used as a loading control 
(LC). 
C. Left - Ror2 mRNA levels are minimally induced under hypoxic-like conditions in RCC4 
cells.  qRT-PCR analysis of the hypoxia mimetic cobalt chloride (CoCl2) transcriptional 
induction after 24hr in the VHL expressing cell line RCC4 3-14 demonstrate induction of the 
HIF target gene Egln3 (**p=0.0015) in response to treatment with hypoxia mimetic, 
confirming HIF transcriptional activity.   Right - Ror2 mRNA levels are minimally induced 
under hypoxic-like conditions in 786-0 WT8 cells.  qRT-PCR analysis of the hypoxia mimetic 
DMOG transcriptional induction after 24hr in the VHL expressing cell line 786-0 WT8 
demonstrate induction of the HIF target genes Egln3 (**p=0.0091) and Glut1 (**p=0.0015) in 
response to treatment with the hypoxia mimetic, confirming HIF transcriptional activity.  Ror2 
transcript levels show minimal enrichment upon treatment.  Transcript values are shown as 
normalized to β-actin RNA internal standard and relative to the unstimulated cells of each 
set of paired cells. 
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Ror2 is regulated by HIF-2α expression 
Since HIFα-mediated transcriptional induction is critical to the role of VHL 
mutation in RCC (29) and Ror2 expression was increased at the transcriptional level 
in a VHL-dependent manner, we sought to further evaluate whether Ror2 expression 
shared any association with HIFα dysregulation.  As the VHL-deficient 786-0 cells 
express only HIF-2α, we used these cells to examine the linkage between HIF 
stabilization and HIF-dependent transcriptional regulation of Ror2 by suppressing 
HIF-2α in 786-0 cells with two independent shRNA constructs (shRNA constructs 
kindly provided by W. Kaelin, Dana Farber Cancer Institute (34)).  Stable knockdown 
of HIF-2α protein was achieved with both shRNA constructs compared to a 
scrambled control shRNA.  Ror2 protein levels correlated linearly with HIF-2α, being 
markedly reduced when HIF-2α levels were suppressed by shRNA (Figure 4.4A).  
We additionally evaluated the effects of HIF-2α knockdown on transcript levels.  This 
experiment demonstrated a reduction in HIF-2α transcript by shRNA suppression to 
at or below physiologic levels, and a corresponding reduction in Ror2 mRNA with 
both shRNA vectors (Figure 4.4B), further implicating this pathway in the mechanism 
of Ror2 expression in RCC.   
As we found Ror2 to be suppressed when HIF-2α was knocked down, we 
also asked if Ror2 expression can be rescued.  Using a HIF-2α double proline to 
alanine (DPA) mutant cDNA plasmid, which is resistant to hydroxylation and VHL-
mediated degradation (generously provided by B. Keith and M.C. Simon, University 
of Pennsylvania), we examined 786-0 cells stably expressing either of the HIF-2α 
shRNA constructs transiently transfected with this HIF-2α DPA mutant.  We 
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observed transient rescue of high levels of HIF-2α expression in the 786-0 HIF-2α 
knockdowns and saw a delayed partial rescue of Ror2 correlated with the highest 
levels of HIF-2α rescue (Figure 4.4C) suggesting that Ror2 is expressed 
downstream of HIF-2α and its expression is directly tied to HIF-2α expression in the 
context of VHL inactivation.   
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Figure 4.4: Ror2 is regulated by HIF-2α expression.   
A. Ror2 expression is suppressed in 786-0 HIF-2α shRNA knockdown cells.  Whole cell 
extracts from RCC cells expressing a VHL transgene (786-0 WT8) or lacking expression of 
VHL (786-0) were further transfected with a control scramble shRNA (scramble) or a HIF-2α 
short hairpin RNA retrovirus (shHIF2) and immunoblotted with HIF-2α, Ror2, and Ku80 (LC) 
antibodies.  
B.  Ror2 mRNA levels are suppressed in 786-0 HIF-2α shRNA knockdown cells.  qRT-PCR 
analysis of the 786-0 HIF-2α shRNA knockdown cells verified effective HIF-2α knockdown in 
two independent knockdown cell lines (**p=0.0022, p=0.0001).  Ror2 expression was 
concordantly suppressed with HIF-2α knockdown (*p=0.0172, **p=0.0023).  
C. Ror2 expression can be rescued by HIF-2α overexpression.  786-0 cells stably 
expressing scramble and shHIF2 were rescued with empty vector (pcDNA) or proline 
hydroxylation resistant double proline to alanine HIF2 mutant (DPA) for 48 and 72 hrs or 
GFP control.  Induction of Ror2 expression is seen when HIF-2α expression is rescued with 
the DPA HIF2 mutant in the two shRNA cell lines.   
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Ror2 is regulated by both HIF-1α and HIF-2α expression 
Observing that Ror2 could be regulated by HIF-2α, we also explored the HIF-
2α dependent regulation in the context of concurrent HIF-1α stabilization and 
examined the more ubiquitously expressed HIF-1α subunit as a potential regulator of 
Ror2 expression.  Though many HIF-1α and HIF-2α targets overlap, some are 
dependent on only one or the other subunit, HIF-1α or HIF-2α, deriving the 
assumption that each of these subunits may have unique or context specific 
functions (28).  Utilizing the RCC4 cell line, which expresses both the HIF-1α and 
HIF-2α subunits, we were able to examine this proposition by suppressing HIF-1α 
and HIF-2α independently using a lentiviral shRNA system which included an iRES 
GFP for stable selection (lentiviral constructs kindly provided by W. Kim, University 
of North Carolina).  Transfecting cells with lentiviral shRNA viral particles with 
suppression titrated by increasing GFP expression, we observed that effective 
suppression of HIF-1α and HIF-2α could be achieved without non-specific 
suppression of the complementary HIF proteins.  However, as has been observed 
previously, some positive compensation in levels of the alternate HIF factor was 
observed (32).  In particular, when HIF-2α was suppressed, an increase in the basal 
levels of HIF-1α were detected, although the net cellular levels of HIF appeared to 
be reduced.  In this system, which preserved the exclusive deregulation of one HIF 
factor, we observed that Ror2 protein levels were highly suppressed when HIF-2α 
levels were reduced (Figure 4.5A) and HIF-1α were sustained, or even enhanced, 
further implicating the HIF-2α pathway in the role of Ror2 regulation.  However, 
when HIF-1α protein levels were suppressed, particularly at the upper end of HIF-1α 
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suppression, there was also a measurable reduction in Ror2 protein expression 
(Figure 4.5A), suggesting that the regulation of Ror2 can also be influenced by HIF-
1α expression.  Utilizing the most highly suppressed cell line for each knockdown 
(based on selection for the highest level of GFP expression), this phenomenom was 
recapitulated at the transcript level, demonstrating suppression of Ror2 transcript 
with shRNA knockdown of either HIF-1α or HIF-2α (Figure 4.5B).  Additionally, 
simultaneous knockdown of both factors produced an additive effect on Ror2 
transcript (data not shown).  This observation that Ror2 transcription is clearly linked 
to HIF stabilization, but that the maintenance of one stabilized HIF factor fails to 
convey a functional redundancy, suggests that the overall amount of HIFα present in 
the cells influences the levels of Ror2 that is expressed.  These results imply that 
Ror2 expression is deregulated in cancer as a result of VHL inactivation and is 
dependent on sustained or pathologically high level expression of either HIF subunit, 
HIF-1α or HIF-2α.   
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Figure 4.5: Ror2 is regulated by HIF-1α and HIF-2α expression.   
A. Knockdown of either the HIF-1α or HIF-2α subunit suppresses Ror2 expression. Cells 
expressing both HIF-1α and HIF-2α were subjected to lentiviral shRNA of each subunit and 
sorted by GFP expression. Three populations sorted for increasing GFP expression were 
assayed for each knockdown and compared to a non-specific sequence (shNS).  When HIF-
2α levels were suppressed, HIF-1α levels remain constant, while Ror2 was downregulated.  
Similarly, when HIF-1α levels were highly suppressed and HIF-2α was stable, Ror2 was also 
downregulated.  
B. Ror2 expression is reduced in a graded manner at the transcriptional level (**p=0.0002, p 
<0.0001) with highest level of suppression, with this effect observed most visibly for HIF-1α 
knockdown.  Suppression of Ror2 was observed at all levels of knockdown of HIF-2α.  qRT-
PCR analysis of the HIF-1α (**p=0.0074, *p=0.0165) and HIF-2α (**p=0.0002, *p=0.0277) 
suppression at the highest level were used to assay for Ror2 and both HIF-1α and HIF-2α 
knockdown lead to a loss of Ror2 expression.    
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HIF complex localizes to the Ror2 promoter 
Observing that Ror2 could be regulated by both HIF-1α and HIF-2α, we 
examined the Ror2 genomic sequence and untranslated regions for evidence of a 
hypoxia response element which could account for HIF-mediated transcriptional 
activation.  None of the previously reported canonical hypoxia response element 
binding sites (5’-CACGTA-3’, or the degenerate sequence 5’-BACGTSSK-3’) were 
detected in the immediate proximity of the Ror2 gene.  Although isolated matching 
sites were found throughout the sequence 10kb upstream and 2kb downstream, we 
decided to assess if HIF proteins could specifically interact with the immediate 5’ 
region of the Ror2 promoter. The HIF-2α only expressing cell line 786-0 was utilized 
for our studies.  Chromatin immunoprecipitation (ChIP), using HIF-1α, HIF-2α, and 
ARNT/HIF-1β antibodies, was performed to analyze HIF interactions with the Ror2 
promoter, utilizing four primer sets covering a 1kb region overlapping the 
transcriptional start site.  HIF-1α immunoprecipitation in this experiment was used as 
a control, as this factor is not expressed in 786-0 cells.  As a positive control, known 
primers targeting the hypoxia response element (HRE) of Egln3 (also known as 
prolyl hydroxylase 3, PHD3) were utilized to confirm HIF complex/chromatin 
interactions (35) providing validation of the system.   
We consistently observed positive interactions with HIF-2α and ARNT in both 
the Egln3 control, as well as with primer set B and less consistently with primer set C 
in the Ror2 promoter (Figure 4.6).  A second set of primers encompassing the same 
general region as primer set B were designed, and also consistently demonstrated a 
positive interaction (data not shown).  Over multiple evaluations, the A and D 
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primers did not demonstrate an interaction with HIF-2α or ARNT in these flanking 
segments of the Ror2 promoter (Figure 4.6).  Upon further examination, the region 
covered by both sets of Primer Pair B was found to encompass an aryl hydrocarbon 
response element (Table 4.1) shown to be important for binding ARNT.  These data 
suggest that we may have identified a cryptic site suitable of HIF complex binding in 
the immediate promoter region of Ror2.   
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Figure 4.6: HIF-2α and ARNT interact with the Ror2 promoter.  Cells lacking expression 
of VHL and overexpressing only HIF-2α (786-0) were subjected to chromatin 
immunoprecipitation with HIF-1α (used as a negative control), HIF-2α, and ARNT 
antibodies.  Primers were designed targeting the 1kb region of the Ror2 promoter which 
overlaps the Ror2 start site.  Using primers targeted against the promoter region containing 
a known hypoxic response element (HRE) of PHD3, also known as Egln3, we show that 
HIF-2α and its dimerization partner, ARNT, interact with the PHD3 promoter as expected. 
HIF-1α interaction is not detected, as this cell line does not express HIF-1α.  When the Ror2 
promoter was examined, HIF-2α and ARNT localized to the Ror2 promoter regions B and C 
similarly to the control promoter.  The region covered by Primer B encompasses an aryl 
hydrocarbon response element (*CACGC) which recognizes the aryl hydrocarbon receptor 
nuclear translocator - also depicted in Table 4.1- Primer Pair B (1).  However, interaction 
was not observed for flanking regions A and D.   
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 Predicted Primer Products 
 
Primer B 
(1) 
 
AGGAGCTGGGGCTGCAGCTGGGGCCCCGGACCTGCCTCCTGCGCCCGCCCTC
GGGCCTGCGCCTCGGAACGCTTGAACACAAAGGTGGCGCCTTGGGGGCGTCA
GCCGGAGTTCGGCGGGTCTGCCCACGCAGGAGAGGCGCCCAGAGCG 
 
 
Primer B 
(2) 
 
GAACACAAAGGTGGCGCCTTGGGGGCGTCAGCCGGAGTTCGGCGGGTCTGCC
CACGCAGGAGAGGCGCCCAGAGCGGGTGCCCCCGACTTTCGGGGGCGACAC
ACCCGGGGATCTAGGTCACAAATC 
 
 
Table 4.1: Predicted product of the Ror2 promoter primers.  Two independent sets of 
primers (highlighted in blue and green, respectively) targeting the 1kb region of the Ror2 
promoter encompassing the aryl hydrocarbon response element (CACGC - highlighted in 
red) were designed to analyze HIF associated proteins and their ability to bind to the Ror2 
promoter.   
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DISCUSSION 
Ror2 is a developmentally regulated kinase normally expressed in 
mesenchymal cells of organs such as the brain, lung, heart, and kidney but is 
normally repressed in most adult tissues, including the kidney (8).  However, this 
kinase is derepressed in a subset of human RCC tumors (8) as well as other 
cancers (9-11), where it is emerging as a major factor promoting tumor cell migration 
and tumor invasion phenotypes.  We sought to identify the mechanism of regulation 
for Ror2, contributing specifically to its stable expression in RCC.  The most 
commonly referenced mutation in RCC pathology is of the VHL gene, with over 70% 
of RCC tumors displaying inactivation of VHL leading to the subsequent stabilization 
of one or more HIF factors, notably HIF-1α and HIF-2α.  The stabilization of these 
potent transcriptional activators leads to the expression of multiple hypoxia response 
genes responsible for such phenotypes of renal tumors as prolific angiogenesis, cell 
invasion, and metastasis (36).    
We first observed that Ror2 was expressed in a VHL dependent manner in 
RCC.  This was further corroborated by our analysis of the VHL somatic point 
mutations that recapitulate the VHL mutant transgenes which represent the major 
subtypes of VHL disease.  This analysis demonstrated that Ror2 is expressed most 
highly in the subtype which maintains expression of the mutant VHL, but promotes 
the most significantly deregulated level of HIF-2α and is thought to lead to a highly 
penetrant form of RCC, Type 2B.  Further, our work has previously shown that the 
VHL Type 2B mutation, which was unable to suppress the Ror2 expression of VHL 
mutant cells, is dysregulated for HIF-2α both in vitro (31) and in vivo (32).  This ties 
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Ror2 to an important aspect of RCC tumorigenesis, as a potential contributor to 
invasive forms of this cancer.  Further, this work linked Ror2 expression indirectly to 
dysregulated stabilization of HIF, as Ror2 expression was observed in cell culture 
VHL somatic mutation models which produce either stabilization of both HIF factors 
(VHL null), or the exclusive stabilization of HIF-2α (VHL 2B).   
Though the HIF-α subunits share certain similarities, they also have divergent 
responsibilities (28).  As Ror2 has been shown to be VHL dependent and our data 
suggested a role for a correlation with HIF stabilization, it provided a natural 
extension to analyze the independent effects of HIF-1α and HIF-2α subunits on Ror2 
expression.  Normally, transcriptional targets that are unique to one of the HIF 
factors are not affected by genetic repression of the uninvolved HIF factor.  
Additionally, transcriptional targets that are mutual to HIF-1α and HIF-2α , such as 
Glut1 or VEGF, typically require the depletion of both factors, due to transcription 
factor compensation, in order to impact expression.  We wanted to tease out the 
difference in expression and analyze if exclusively one or both HIF-α subunits had 
an effect on Ror2 expression. Our investigations point toward a clear correlation 
between HIF-2α stabilization and Ror2 expression in 786-0 cells, in which genetic 
knockdown and rescue experiments confirm this linear association.  In cells 
expressing both HIF-1α and HIF-2α, the depletion of either factor was sufficient to 
reduce Ror2 expression at the transcript and protein levels.  This suggests that with 
graded suppression of either HIF-1α or HIF-2α, Ror2 is coordinately expressed in a 
similar manner, and that functional redundancy between the factors may be dose 
dependent.  Such a pattern of regulation is not typical of most transcriptional 
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components of the hypoxia response pathway, although similar patterns of atypical 
regulation have been previously reported for HIF targets (28).  In the case of Ror2, 
the depletion of either factor from the maximally stabilized state causes the loss of 
Ror2 expression, indicative of a dosage effect of HIF factors on the transcriptional 
activation of Ror2. 
Prior hypoxia target investigations suggest that the Ror family ortholog cam-1 
is a HIF-dependent hypoxia target in C. elegans (37).  However, though the HIF 
pathway has been studied extensively, Ror2 has yet to be identified as target of the 
hypoxia response pathway in mammalian cell screens.  Activation of the hypoxia 
response pathway via stabilization of one or both of the HIF-α subunits is a 
commonly observed phenotype in RCC tumors, and physiologic upregulation of HIF 
factors as a result of strict decreases in oxygen availability is an important cellular 
process in a variety of disease states.  We thus extended our analysis to address 
this issue.  Despite the observation of clear linear connections between HIF 
stabilization and Ror2 expression, we observed minimal induction of Ror2 
expression in these studies, even after prolonged exposure to hypoxia, or chemical 
poisoning of the prolyl hydroxyation activity with potent inhibitors.  These data 
suggest that within the context of this tumor cell system, physiologically relevant 
exposure to hypoxia may not be sufficient to induce changes in Ror2 expression 
levels compared to the normoxic controls.  This surprising result may shed further 
light on the mechanism of Ror2 regulation as a cancer associated kinase.  Sustained 
oncogenic levels of HIF factors are not routinely attained in response to hypoxic 
insult.  However, in renal cell carcinoma, as a result of VHL inactivation, or in other 
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tumors, notably squamous cell carcinoma of the head and neck, HIF is induced to 
high constitutive levels, which may account for the identification of a novel HIF target 
associated with cancer.   
Whether it is the distinctly high levels of HIF factors associated with VHL loss 
or the maintenance of high levels for sustained periods of time which contributes to 
Ror2 expression is not certain.  However, constitutive stabilization of HIF factors 
occurs broadly across many types of tumors, such that Ror2 as a tumor associated 
kinase may be encountered even more frequently.  One potential reason hypoxia 
may fail to upregulate Ror2 expression is that Ror2 transcriptional regulation may be 
steps removed from HIF induction.  Certainly several factors downstream of HIF 
activation could be considered as intermediate transcriptional regulators of the 
expression of Ror2, though which of these factors may contribute to regulation of 
Ror2 expression either developmentally or in the tumor physiology scenario remains 
to be determined.  However, in our analysis of the Ror2 promoter, we found that 
HIF-2α and ARNT can be localized to a small region of the immediate Ror2 promoter 
region, which lacks any known hypoxia response element binding sequence.  This 
interaction of the HIF complex at a cryptic Ror2 promoter site is suggestive of a 
direct mechanism of HIF regulation.  However, this finding does not preclude the 
possibility that one or more additional transcriptional co-factors may be required to 
coordinate activation in a manner which is dependent on VHL loss or HIF 
stabilization, or that more distant conserved HRE sites may be utilized for HIF-
dependent transcriptional regulation. 
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An additional possibility exists to link the dependence on VHL inactivation and 
HIF stabilization in clear cell renal cell carcinoma, and the failure of Ror2 to exhibit 
hypoxic induction.  VHL mutation also mediates alternate effects on cell signaling 
external to the well studied effects on HIF regulation.  For example, pVHL is known 
to affect the stabilization of a non-HIF associated protein, JADE-1 (38), and in a 
sophisticated genetic screen in C. elegans, at least four HIF-independent but VHL-
dependent genes were identified (39).  Thus, our results may reflect the activation of 
a gene that is HIF dependent only in the setting of a VHL mutation because of other 
context specific cues.  Further, patterns of tumor cell invasion have been suggested 
to be dependent on aspects of VHL loss which are not clearly dependent on HIF 
stabilization.  The extent to which Ror2 may play a role in promoting these invasive 
features of tumors will need to be further investigated. 
RCC is a difficult to treat cancer that offers few effective options for treatment.  
We previously reported that Ror2 expression has a distinct role in RCC tumor cell 
biology (8) and has potential to be important for components of tumor invasion.  We 
have since demonstrated a mechanism of Ror2 regulation that, with respect to clear 
cell RCC, can be linked to VHL loss and is a component of the HIF dependent 
transcriptional program in clear cell RCC cell lines.  This sustained stabilization of 
HIF is a feature of many tumors, some of which are independent of VHL mutation, 
and is associated with advanced disease.  Here we offer a unique mechanism of 
regulation that offers insight into how Ror2 is deregulated in RCC that has the 
potential for application in many other cancers.   
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MATERIALS AND METHODS  
Antibodies  
Both monoclonal and polyclonal antibodies against Ror2 were obtained from RND 
Systems (Minneapolis MN).  Antibodies against HIF-2α and Ku80 (loading control - 
LC) were obtained from Genetex (San Antonio TX). The HIF-1α antibody was 
obtained from BD Transductions (Franklin Lakes NJ) and the Glut1 and the Egln3 
antibodies were obtained from Novus Biologicals (Littleton CO). For figures 4.3B and 
4.5, a HIF-2α antibody obtained from RND Systems (Minneapolis MN) was used for 
analysis. 
 
Chromatin Immunoprecitation (ChIP) Analysis 
Cells were grown to 80% confluency before being crosslinked with 11% 
formaldehyde.  The crosslinked DNA was then sonicated.  Chromatin 
immunoprecipation (ChIP) analysis was performed with HIF-1α (BD Transduction, 
Franklin Lakes NJ), HIF-2α (RND Systems, Minneapolis MN) and ARNT1 (Novus 
Biologicals, Littleton CO).  The resulting ChIP DNA was analyzed by PCR using 
primers targeting the known HRE region of Egln3/PHD3 (Reverse Primer: 5’ 
TAGGCACAGTAAACAGGCCC 3’; Forward Primer: 5’ 
AGCGTCCGTTCCCAGCTCAG 3’) as previously described (35) as positive controls 
to validate the system.  Additionally, primers were designed to target the 1kb region 
of the Ror2 promoter – Primer A (Reverse Primer: 5’ 
ACGCGCTTGTCCCCACCGAC 3’; Forward Primer: 5’ 
CTGCACTGCGCACCGGGACA 3’), Primer B  (Reverse Primer: 5’ 
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CGCTCTGGGCGCCTCTCCT 3’; Forward Primer: 5’ 
AGGAGCTGGGGCTGCAGCTGGG 3’), Primer C (Reverse Primer: 5’ 
AGCCCGCGCCAAGGAACCTC 3’; Forward Primer 5’ 
ACGATGCGTCCGCTCCTCCT 3’) and Primer D (Reverse Primer: 5’ 
TCTGGCGTTCCGGCTTGTGC 3’; Forward Primer: 5’ 
CGTCGGGCGAGATGCGAATGG 3’).   
 
Cell Culture and Cell Treatments 
The 786-0 cell line and their paired derivatives, WT8 & RC3 (kindly provided by Dr. 
W. Kaelin, Boston MA), the 786-0 VHL point mutants knock-in cell lines and the 
RCC4 paired cell lines, 3-14 and 2-1 (kindly provided by Dr. M.C. Simon and Dr. B. 
Keith, Philadelphia, PA) were maintained in Dulbecco’s Modified Eagle Medium with 
10% fetal bovine serum, L-glutamine and non essential amino acids.  For treated 
cells, the following conditions were utilized: cobalt chloride, CoCl2 (Thermo Sci Acros 
Organics, Geel Belgium) was used at 100μM for times specified,  
dimethyloxalylglycine, DMOG (Cayman Chemical Company, Ann Arbor MI) at 1mM 
for 24 hours, or cells were incubated under conditions of 1% hypoxia for times 
specified.   
 
Immunoblot Analysis 
Proteins were extracted from cultured cells using cell lysis buffer consisting of 20mM 
Tris, 100mM NaCl, 1 mM EDTA, 1% NP-40 and a protease inhibitor cocktail (Roche 
Diagnostics, Indianapolis IN).  Samples were quantitated using Bradford reagent to 
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measure absorbance.  40-50ug of protein samples were then separated on 8% 
SDS-polyacrylamide gels, transferred to nitrocellulose membrane (GE, Pittsburg PA) 
and the proper horse radish conjugated secondary antibodies were used.  Proteins 
were detected using the Amersham ECL-Plus System (Pittsburg PA) and visualized 
on autoradiography film (ISC BioExpress, Kaysville UT).   
 
qRT-PCR 
cDNA was made by reverse transcription from 0.5ug of total RNA (5PRIME Perfect 
Pure RNA Cultured Cell Kit, Gaithersburg MD) using oligo dT primers and the 
Superscript II RT-PCR reagents (Invitrogen, Carlsbad CA).  Commercially available 
proprietary FAM labeled primers (Ror2, Egln3, Glut1, HIF1, HIF2 and β-actin) were 
used for amplification and the samples analyzed on the 7900H Fast Real-Time PCR 
System using recommended cycle conditions (Applied Biosystems, Foster City CA).   
  
Transfections and shRNA 
shRNA knockdown cells were generated by infecting cells with pRetroSuper (pRS) 
packaged shRNA for HIF-2α (kindly provided by Dr. W. Kaelin, Dana Farber Cancer 
Institute (34)). Cells were supplemented with puromycin in the media to maintain the 
shRNA for stable suppression. Rescue of HIF-2α shRNA cell lines were generated 
transiently by using a HIF-2α (mutated double proline to alanine, DPA) expressing 
plasmid in a pcDNA3 backbone (kindly provided by Drs. B. Keith and M.C. Simon, 
University of Pennsylvania).  RCC4 lentiviral knockdown cells were generated by 
infecting the cells with pLL 5.0 packaged shRNA (with a GFP-expressing tag) for 
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HIF-1α and HIF-2α (generously provided by Dr. W. Kim, University of North 
Carolina) and GFP-positive cells were selectively sorted via GFP expression levels 
by the UNC Flow Cytometry Core Facility.  
 
Statistical Analysis 
A one-way ANOVA was used to analyze the standardized cT values with the 
specified qRT-PCR target (Ror2, Egln3, Glut1, HIF1, HIF2) as the fixed constant.  
Verification of the one-way ANOVA model was performed using Kruskal-Wallis test, 
a nonparametric statistical procedure, to compare the standardized cT values. Error 
bars represent standard error of means (SEM).  P-values referenced as are 
followed:  *p<0.05, **p<0.01.   
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CHAPTER 5 
 
SUMMARY, DISCUSSION AND CONCLUSIONS
SUMMARY 
In the search to uncover potential biomarkers or cell intrinsic kinases for the 
difficult to treat epithelial cancer, RCC, we have discovered a novel putative cancer 
cell specific kinase target, Ror2.  Biomarkers and cancer cell specific kinases are 
severely lacking within the renal carcinoma cancer field as well as other cancer 
etiologies.  Depending on the cancer field being studied, few biomarkers have been 
identified and characterized with the specific intent of finding an amenable target.  
My goal was to identify and characterize cancer cell specific kinase(s) expressed on 
RCC with the ultimate goal of using the specific kinase(s) for future therapeutic 
development. 
For our analysis, we utilized a phospho-RTK array using pVHL mutant cell 
lysates from cell lines to try to identify potential kinases.  Within this array, we had 
several RCC specific positive and negative controls as well as internal controls 
provided by the company.  EGFR is normally expressed abundantly on RCC and 
there was robust expression of EGFR on the RTK array as would be expected.  
However, VEGFR and PDGFR, which are not normally expressed on RCC, were 
also not expressed on the RTK array as expected.  Though several receptor tyrosine 
kinases were identified from this screen that had the potential to be useful as RCC 
cancer therapeutics, we chose to look more closely at Ror2 as it was the most novel 
at the time of discovery and had not been previously associated with any cancer.  In 
fact, Ror2 is a developmentally regulated kinase usually expressed in the developing 
kidney, heart and lungs.  However, expression of Ror2 is not normally seen in adult 
tissues.  
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Two bone disorders that result in shortened or misshapen bones arise if 
hRor2 is mutated.  Robinow disease results from missense, nonsense and 
frameshift mutations in the CRD, kringle and kinase domains whereas autosomal 
dominant Brachydactyly B arises from truncations of the entire kinase domain or just 
below the tyrosine kinase domain.  Genes important for skeletal development have 
also been shown to have a significant impact on cancer.  In fact, many labs are 
currently in the process of characterizing genes important for skeletal development 
including multiple Wnt and Hox genes that also impact cancer growth.  It is intriguing 
that Ror2 has also been identified as having a key role in RCC’s cancer etiology as it 
also plays a key role in skeletal development.  Ror2 has previously been identified 
as having a potential role in the Wnt signaling pathway in several model systems 
where it is shown to bind different Wnts depending on context, but again what role 
Ror2 itself may play in RCC still remains to be elucidated. 
As Ror2 was initially identified from a phospho-RTK array, we verified by 
immunoprecipitation that it was phosphorylated in RCC cell lines.  We show that 
expression was not specific to one cell line as Ror2 was also found to be expressed 
in multiple RCC cell lines tested.  Most notably, expression of Ror2 was not detected 
in our SV40 transformed control proximal tubule cell line, suggesting this was 
specific to RCC as it was not expressed in the “normal” control kidney cell line.  
Seeing expression in RCC cells lines, we also wanted to know if Ror2 could be 
detected in primary human tumors.  Indeed, we show that Ror2 is expressed in a 
majority of RCC tumors analyzed both at the protein and mRNA level.   
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Additionally, by microarray analysis, we show human RCC tumors 
coordinately overexpresses with MMPs which demonstrates an ECM tumor 
phenotype for Ror2.  This is fascinating as Ror2 is shown to be related to skeletal 
development and is now related with MMP2, which has also been shown to be 
important for skeletal and bone development.  Additionally, MMP2 is a key 
component in the degradation of the cell basement membrane, or the extracellular 
matrix.  The connection to MMP2 was further corroborated in RCC cell lines - when 
Ror2 was suppressed, MMP2 expression was also suppressed suggesting that Ror2 
may play a role in directing MMP2 expression.  Functional analysis assays suggest 
that Ror2 supports cellular migration, without affecting doubling time or cell viability.  
Further, Ror2 suppression has an impact on anchorage independent growth, a key 
component of tumor growth potential, leading to a dramatic decrease in overall 
colony size.  Utilizing a xenograft model, we also show that Ror2 suppression 
influences tumor growth in vivo.  Together, this data strongly suggests that Ror2 
plays a considerable role in RCC tumorigenesis (1).  
A model of regulation had yet to be determined for Ror2.  Therefore, we also 
sought to place Ror2 in the most common deregulated pathway in RCC, the VHL 
pathway.  We show that Ror2 is dependent on the inactivation of pVHL.  
Additionally, Ror2 regulation by VHL is defined by specific VHL subtypes that are 
highly predisposed to RCC.  Further, the only known substrates of VHL inactivation, 
the HIFα subunits, were also assessed.  We show that Ror2 is dependent on the 
stabilization of both HIF1α and HIF2α.  This Ror2 dependency could be rescued with 
constitutively active HIF subunits.  However, Ror2 could not be induced under 
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physiological hypoxic conditions suggesting that it may only require a component of 
the VHL/HIF pathway or it may not be a linear pathway.  Seeing this interesting 
finding, we assessed the Ror2 promoter and found that HIF associated proteins 
(HIF2 and its binding partner ARNT) can and do bind and/or localize to the 
immediate Ror2 promoter.  These findings suggest a novel mechanism of regulation 
for Ror2 not previously uncovered (2).  
The identification of Ror2 opens up the cancer field to an avenue of Wnt 
signaling, not previously identified before now, that is relevant to RCC and also 
provides a tangible biological avenue to extracellular matrix remodeling.  
Additionally, the identification of a novel pathogenic HIF activation pathway not 
commonly seen in other cancers could be exploited in other pathogeneses.  Not only 
has the identification of Ror2 introduced a potential druggable target, but also 
identifies a potential biomarker for RCC treatment and for other cancers. 
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DISCUSSION 
VHL regulation of Ror2 is predictive of a more aggressive tumor type 
Within the spectrum of VHL disease, there is a tight genotype/phenotype 
correlation where representative VHL mutations are associated with specific VHL 
disease subtypes.  Our data shows that Ror2 is regulated by both VHL and HIF 
expression in RCC (2).  Based on this finding, we also closely assessed the VHL 
disease subtypes and analyzed Ror2 expression.  VHL disease patients fall into 
distinct genotypic categories that can predict the range of RCC presentation (3, 4) 
and have correlated HIF2 dysregulation.  VHL Type 1 and Type 2B are highly 
dysregulated for HIF2α and both VHL subtypes are at high risk for developing 
ccRCC.  Further, VHL Type 2B mutations are associated with the most diverse 
presentation of VHL disease and are thought to be the most highly penetrant for 
developing RCC.  Indeed, in previous studies it is postulated that type 2B tumors 
may be more aggressive than their other Type 2 counterparts.   
Previous work from our lab shows that VHL type 2B mutation is dysregulated 
for HIF2 expression much so as the VHL Type 1 mutation (5).  Further, these studies 
suggest a tight connection between the ratio of HIF expressed and its stability.  
When we assessed Ror2 expression in the representative somatic mutational VHL 
subtypes, we saw high expression of Ror2 only in the VHL Type 1 and Type 2B.  
Both of these subtypes are highly predisposed to ccRCC and have a high level of 
HIF2α dysregulation.  It is interesting to see that Ror2 is associated with VHL 
subtypes that can lead to the most aggressive forms of ccRCC.  More notably, 
HIF2α itself is considered to be the more tumorigenic of the two HIFα subunits as 
 153
downregulation of HIF2α is necessary for tumor suppression by pVHL (6-8).  These 
findings not only imply a possible role for Ror2 in the VHL disease subtypes, but also 
suggest that the potential RCC target kinase Ror2 is associated with the more 
tumorigenic of the HIF subunits leading to a more aggressive form of RCC.  
 
Ror2 expression defines an ECM tumor phenotype in RCC 
Our analysis of Ror2 shows that it is linked to the loss of VHL expression.  
ECM remodeling itself has also been tied directly to VHL expression as restoring 
pVHL to pVHL-deficient cells partially restored the ECM organization phenotype 
previously lost because of pVHL inhibition (9, 10).  Additionally, previous data shows 
that VHL directly interacts with and has a role in the assembly of the extracellular 
matrix (9, 10).  Further, cells with mutated VHL have increased expression of MMPs 
including MMP2 (11).  Ror2 is dependent on the loss of pVHL expression and can 
direct MMP2 expression, immediately suggesting a potential role for Ror2 at the 
ECM.   
Seeing that Ror2 was expressed in a large majority of the human RCC 
tumors, we wanted to assess if Ror2 also plays a role in RCC tumorigenesis.   RCC 
is a lethal epithelial cancer that is the most common kidney malignancy (12) with 
over half of those diagnosed presenting with metastasis.  For epithelial cells to 
metastasize, they must first acquire mesenchymal characteristics that permit 
proliferation outside of their normal periphery.   Ror2 is primarily expressed in rising 
mesenchymal cells in the developing kidney immediately suggesting a potential role 
for Ror2 in RCC tumor development.  Indeed, genes important for ECM remodeling 
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including MMP2 and Twist1 were found to be tightly correlated with Ror2 
overexpression and both have been linked to RCC.  MMPs are widely known to be 
key factors in tumor expansion and promote metastasis by degrading the structural 
basement membrane.  In recent years, a tight link has been established connecting 
MMPs to RCC.  In fact, previous studies show that increased MMP2 expression is 
correlated with patients that have poor prognostic variables such as survival, 
aggressiveness and grade in RCC (13, 14).   Seeing that Ror2 has a direct role in 
MMP2 expression is exciting as it tightens the link between Ror2 and RCC tumor 
biology.  Thus, Ror2 overexpression and its link to MMP2 may represent an 
important transitional event in the development of invasive renal cell carcinoma.   
 
HIF uniquely regulates Ror2 expression 
In an effort to uncover the mechanism of Ror2 regulation in RCC, we chose to 
analyze the VHL/HIF pathway - as VHL is the most commonly mutated gene leading 
to HIF dysregulation - to identify pathways in which Ror2 had not been previously 
implicated.  Our analysis uncovered a novel and uncommon method of HIF 
regulation for RCC that may have broader applications.  We found that Ror2 is not 
only regulated by pVHL expression but is also dependent on the stabilization of 
either HIF1 or HIF2, even though Ror2 expression is minimally induced under 
physiological hypoxic conditions.   
The most well-documented function of pVHL is to act as the substrate 
recognition component of an E3 ubiquitin ligase complex (15-18).  The most 
identifiable substrates of pVHL are the hypoxia inducible factor (HIF) subunits.  The 
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HIF subunits are oxygen sensing transcription factors that play vital roles in the cell.  
When the HIF1α and HIF2α were suppressed individually, Ror2 expression was 
reduced in both the HIF1α only and HIF2α only RCC4 cell lines.  This level of 
regulation can be seen at both the protein and mRNA levels via immunoblot and 
qRT-PCR analysis.  Normally, transcriptional targets that are unique to one of the 
HIF factors are not affected by genetic repression of the uninvolved HIF factor.  
Additionally, transcriptional targets that are mutual to HIF-1α and HIF-2α, such as 
Glut1 or VEGF, typically require both factors to be depleted to have an influence on 
expression due to transcription factor compensation.  However, in our studies, we 
found that when either HIF-1α and HIF-2α is suppressed individually, we see a 
graded level of Ror2 expression with increasing HIF suppression.   
This graded regulation of Ror2 by the HIF subunits is uncommon for HIF 
regulated genes as regulation by HIF1α and/or HIF2α require both to be present or 
completely depleted to fully function in its regulatory role.  However, both HIF factors 
do not need to be depleted to have an impact on Ror2 expression.  Within the 
literature, few other genes have been identified that share this atypical regulatory 
property.  Within the pseudohypoxic RCC tumors themselves, there is a difference of 
expression between HIF1 and HIF2 expressing tumors and HIF1 only tumors.   A 
recent study performed by Gordan et al. analyzing human RCC tumors 
demonstrates that the molecular profile of tumors is highly dependent on the 
expression of HIF1 and HIF2 in comparison to those tumors solely expressing HIF2, 
with distinctions that correlate with divergent tumor activity (19).  The distinctive 
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graded HIF regulation seen with Ror2 could represent a new category of genes 
indicative of a unique class of regulation.   
The HIF factors play important roles in many cellular contexts in addition to 
VHL loss and renal cell carcinoma including angiogenesis and invasion and 
metastasis (20).  Both HIF subunits (HIF1 and HIF2) dimerize with HIF-1β/ARNT 
and bind conserved hypoxia response elements (HREs), oxygen dependent 
promoters/enhancers of target genes, leading to the induction of hypoxia inducible 
target genes including Glut1 and prolyl hydroxylase family member Egln3 (also 
known as PHD3).  Seeing that Ror2 has a distinctive HIF regulation and to explore 
the possible contribution of this factor to the global cellular response to hypoxia, the 
hypoxic induction of Ror2 was analyzed.  It was surprisingly difficult to stimulate 
Ror2 expression levels under low oxygen conditions.  Using a variety of low oxygen 
induction methods, including 1% hypoxia and hypoxia mimetics such as cobalt 
chloride, Ror2 levels were minimally induced at best.  To further delineate the 
hypoxic response pathway, we utilized a more potent hypoxia mimetic, DMOG.  
After DMOG stimulation for 24 hrs, minimal induction of Ror2 was seen again at the 
transcriptional level utilizing qRT-PCR.  However the controls Egln3 and Glut1, direct 
targets of the hypoxia response pathway were sufficiently induced under hypoxia-
like conditions as expected since 786-0 WT8 cells express a wild-type VHL gene.  
Several possibilities arise from this interesting finding.  We may need to induce 
hypoxia for an extensive time period – as the Huang lab at the University of Utah 
provided data suggesting hypoxia can be induced long-term (as far as two weeks) 
(21).  Conversely, Ror2 may be an indirect target of the HIF activation pathway so 
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may require even more HIF activation than the cells can withstand in a hypoxic 
environment or Ror2 may complex with an unidentified cofactor that may inhibit 
hypoxia with pVHL inactivation.  This intriguing finding prompted examination of the 
Ror2 promoter to analyze if Ror2 specifically interacted with HIF proteins.   
 
HIF proteins bind or localize to the Ror2 promoter 
Seeing that Ror2 is minimally induced under physiological hypoxic conditions 
but is dependent on the stabilization of the HIF subunits, we wanted to closely 
analyze the Ror2 promoter region to determine if HIF associated proteins also bind 
or localize to the Ror2 promoter.  We analyzed the 1kb region of the Ror2 promoter 
that contains the transcriptional start site as it encompasses an aryl hydrocarbon 
response element which recognizes the aryl hydrocarbon receptor nuclear 
translocator.  To begin, we first utilized primers against a known HIF target, a prolyl 
hydroxylase family member, PHD3 (also known as Egln3) as a control (22) to test 
the interactions of this genes’ promoter with HIF2 and ARNT in the HIF2 only 
expressing cell line, 786-0.  Specifically, we chose published PHD3/Egln3 primers 
(22) targeted against the hypoxic response element (HRE) of Egln3, where HREs 
are oxygen dependent promoters/enhancers of target genes.  Using the Egln3 
primers, we show that HIF2 and its dimerization partner, ARNT, interacts with the 
Egln3 promoter as expected but not with HIF1 as this cell line does not express 
HIF1.  For our Ror2 promoter analysis, we designed primers that emcompassed the 
transcriptional start site of Ror2 and asked if HIF localizes to the promoter.  Indeed, 
when the Ror2 promoter was assayed, we show that the HIF associated proteins, 
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HIF2 and ARNT, bind or localize to the Ror2 promoter similarly to the control 
promoter, Egln3.  Not only have we shown that Ror2 expression is dependent on the 
physiological stablization of the HIF subunits but we now show that HIF associated 
genes bind and/or localize to the Ror2 promoter.  This finding is especially intriguing 
as our data suggests that Ror2 is HIF dependent but minimally induced under 
hypoxia.   
This could be because Ror2 may be part of an epigenetic component that has 
a different and possibly unknown posttranslational modification, though this is only 
speculative.  Indeed, a novel regulation may be established as the Ror2 promoter 
encodes an aryl hydrocarbon response element (AHRE) that is perhaps responsible 
for its interaction with HIF but not necessarily for its induction under physiological 
hypoxic conditions.  Several possibilities exist that may explain the Ror2 results we 
see.  ARNT may be preferentially sequestering the HIF-2 subunits away from 
putative HREs leading to minimal hypoxic induction of Ror2 when placed under 
cellular stress.  Furthermore, the AHRE may represent a novel binding site of 
interaction between HIF/ARNT such that Ror2 transcriptional expression is not 
induced under physiological hypoxic exposure, though this novel interaction is only 
speculative with respect to Ror2.   
The HIFα subunits contain a conserved asparagine residue that under normal 
oxygen conditions, factor inhibiting HIFα (FIH) hydroxylates preventing interaction 
with known transcriptional co-factors, CBP/p300, as well as with many other 
cofactors.  It is possible that the FIH domain in the HIFα subunit may play a 
prominent role by recruiting an unidentified cofactor which may interact with Ror2 in 
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a unique way.  Additionally, these results are based on our analysis of the VHL/HIF 
pathway and it is possible that other HIF activated pathways may play a contributory 
role.  In conclusion, our efforts to analyze the mechanism of Ror2 regulation in RCC 
has uncovered a novel and uncommon method of HIF regulation where Ror2 is HIF 
dependent but not upregulated by physiologically induced hypoxia.  This is intriguing 
as this novel method of regulation may have broader applications to other cancer 
etiologies.   
 
Ror2 is a new kinase target in RCC 
Growth promoting pathways are currently not examined closely in tumor 
oncology.  Observing Ror2 and other developmentally regulated genes is of 
increasing value as a largely untapped area of solid tumor oncology is the explicit 
investigation of growth promoting pathways. These promoting pathways are 
distinctive and critical to early developmental patterning.  Classifying the signaling 
molecules that play a physiologic role in early developmental processes, with 
potential to promote tumor growth or other pathologic characteristics in the adult, 
provides oncologists and the general cancer community an opportunity to define 
biological cause for various tumor attributes (23).  Further, identifying molecules 
such as Ror2 that have restricted tissue expression in the adult organism provides a 
valuable chance for diagnostic or therapeutic implementation. 
Within the renal carcinoma field as well as other cancer fields, few specific 
cell intrinsic kinase targets have been identified as amenable targets.  Though 
targeted therapies exist for RCC, drug target optimization for clinical relevance and 
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further patient benefit still needs to be addressed.  A prime example of this is 
sunitinib – though it has been shown to have efficacy in RCC treatment, it targets 
multiple kinase receptors, some of which are not expressed on RCC including 
VEGFR and PDGFR.  However, within the field of RCC, the paradigm is shifting to 
wanting to specifically select patients for treatment based on specific molecular 
markers.  As such, we undertook the task of searching for cell intrinsic kinases that 
may have the potential to be used as the basis for targeted therapy.  In the hunt to 
identify novel cancer cell specific kinases, we identified several putative kinases.  
One identified kinase, Ror2, was chosen for characterization as it had not been 
previously associated with any cancer, but is developmentally regulated, and we 
show that it has a dramatic impact on RCC tumorigenesis and its regulation is VHL 
and HIF dependent.  This finding of a potential kinase target is of importance to not 
only the RCC field but other cancer fields as well because Ror2 is normally 
expressed during development but is now de-repressed and is highly associated 
with cancer – having a significant role in RCC’s tumorigenesis and regulated by HIF 
in a unique manner.  Together, having an impact on RCC tumorigenesis and being 
tightly associated with the VHL/HIF pathway is of significant value as current 
targeted therapies against RCC are heavily focused on this pathway.  Thus the 
discovery of a newly identified cancer cell intrinsic kinase in RCC, and now in other 
cancer etiologies, could have a drastic impact on the RTK inhibitor field.   
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WHAT THE FUTURE MAY HOLD  
Ror2 is associated with an invasive phenotype in multiple cancers 
Since the identification of Ror2 in RCC, Ror2 has since been identified in 
several cancers including metastatic melanoma, invasive gastric cancer, malignant 
squamous cell carcinoma and osteosarcoma (Table 1.2).  Within all these tumors, 
Ror2 has been shown to be associated with an invasive phenotype (24-29).  
Specifically, in metastatic melanoma, Ror2 has a dramatic impact on cell motility, 
cellular invasion and metastasis (24) while in invasive gastric cancer, Ror2 has a 
role in cell invasion (25, 26).  Within malignant squamous cell carcinoma, Ror2 has 
been associated with cell motility and cell polarity (27).  In osteosarcoma, an 
adolescent bone cancer, Ror2 has been associated with cell proliferation, cell 
migration, invadopodia formation and ECM degradation (28, 29).  All this data links 
Ror2 once again to an invasive phenotype but also ties it to skeletal development as 
it plays a prominent role in both bone cancer and at the ECM.   Finding Ror2 in 
multiple cancers and being associated with an invasive phenotype suggests the 
potential to target Ror2, in not only RCC, but also opens up the door to target Ror2 
in other cancer etiologies as well.        
More pointedly, with respect to RCC, Ror2 is associated with the VHL disease 
subtype 2B, which is thought to be more invasive than its associate subtypes and is 
also highly coordinated with and possibly directs MMP2, a key component in the 
degradation of the extracellular matrix.  Interestingly, MMP2 is also associated with 
bone development and is thought to play a key role at the ECM.  Ror2 itself makes 
an amenable target as it has similar functions in different cancers that have been 
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independently assessed by multiple groups. At the time of discovery of Ror2 in RCC, 
Ror2 was shown to be associated with the Wnt signaling pathway and embryonic 
mutations in Ror2 leading to bone disorders.  Intriguingly, Ror2 is now tied to both 
skeletal development and is associated with an invasive cancer phenotype in 
multiple cancers.  This suggests that Ror2 certainly warrants closer focus in the 
clinics and possibly when thinking of future therapeutics.   
 
Ror2’s role in the EMT process 
To analyze the signaling role of Ror2 in RCC, we had performed microarray 
analysis on RCC human tumors and analyzed gene expression.  In our initial studies 
we found that Ror2 correlated with genes important at the ECM, but we also 
identified genes important for the epithelial to mesenchymal transition (EMT).  When 
genes that most significantly associated with overexpressed Ror2 were examined, 
we saw genes important for the epithelial to mesenchymal transition including 
Twist1, Twist2, Snail2 and MMP2.  Interestingly, epithelial to mesenchymal transition 
(EMT) also plays a critical role in tumor development and metastasis (30, 31).  
Within EMT, certain hallmarks define EMT transformation including the expression of 
the transcription factors Snail and Twist, which mediates the morphological changes 
seen in tumors (32-34).  Specifically within renal cells, HIF also play a role in 
directing the expression of these transcription factors (35-37).  Moreover, HIF1 has 
been shown to directly mediate Twist and Snail expression as well as the onset of 
EMT seen with hypoxic injury (35-37).  Seeing these factors expressed when Ror2 is 
coordinately expressed suggests further association and more feasibility for analysis 
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of this phenomenon.  However, the direct role Ror2 may play in the EMT process 
has yet to be elucidated.   
To analyze this further, we plan to study the role of Ror2 in the EMT process 
specifically within RCC.  Within the context of assessing Ror2’s role in EMT, defined 
criteria need to be addressed.  EMT is defined by changes in cell motility and cell to 
cell adhesion changes.  As such, we plan to assay for increased cell motility, loss of 
cellular adhesion, and repression of E-cadherin and/or integrins.  All three criteria 
will be addressed using functional assays (live cell migration, tight or adherence 
junction analysis).  The experiments outlined above will aid in identifying the role of 
Ror2 in the EMT process as EMT plays critical roles in tumor development and 
metastasis.  Based on previous data, Ror2 may play a direct role in this process as 
well.   
 
Ror2 association with a more aggressive form of ccRCC 
Our lab has also undertaken the task of trying to identify potential molecular 
subtypes within ccRCC.  Looking closely at the clinical presentation and analyzing 
previous gene expression data suggested that more than one molecular subtype of 
clear cell RCC existed.  As such, a recent microarray study was performed by 
Brannon et al. on 48 clear cell RCC tumors to address this issue (38).  An 
unsupervised consensus clustering – where similar tumors are grouped - was 
performed on these primary tumors without any previous knowledge or clinical 
information such as grade and survival.   From this analysis, two distinct ccRCC 
molecular subtypes were recognized.  Seeing this distinction between the ccRCC 
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tumor subtypes prompted validation which was performed in 177 tumors and again 
the same two distinct molecular subtypes were present.   
To further assess potential reasons and a rationale of why two distinct 
molecular subtypes were recognized, survival analysis was performed on the 177 
tumors and there was a significant difference in survival.  The two subtypes were 
designated as ccA and ccB, with ccA conferring a significantly better survival rate 
over ccB.  The analysis was taken farther utilizing SAM (Significance Analysis of 
Microarrays) and pathway analysis.  ccA tumors overexpressed RCC-like genes 
such as those associated with hypoxia and angiogenesis while ccB overexpressed 
genes associated with more aggressive pathways including genes that regulate 
wound healing, the cell cycle and EMT (38).  Interestingly, Ror2 was also 
overexpressed in ccB molecular subtype, which confers to a more aggressive and 
immature phenotype.  This again places Ror2 in a more aggressive subtype of RCC 
and suggests that Ror2 may play a key role in the poor survival seen in ccBs.  This 
analysis not only distinguishes two molecular phenotypes that confer to a significant 
survival difference but once again distinctly associates Ror2 with a more aggressive 
subtype of RCC.   
In the future, we would like to look more closely at a cohort of primary paraffin 
embedded ccB tumors that also have corresponding clinical information.  Ror2 will 
be tested as a potential tumor biomarker of EMT events in the tumor.  We would like 
to analyze these tumors by IHC for Ror2 expression to assay its potential to be a 
biomarker.  Additionally, since Ror2 is regulated by both HIF factors, we will also 
assay for both HIF1 and HIF2 expression as well as markers of EMT including E-
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cadherin.  A Ror2 protein profile will be generated using these primary human 
tumors.  This will be correlated with clinical information such as gender, metastatic 
potential and survival.  Our previous data indicates that Ror2 is in a majority of 
ccRCC tumors (over 55%) suggesting the feasibility of accomplishing this goal.  It 
will be interesting to see the role Ror2 plays in the ccRCC and its potential clinical 
benefit once these technologies are up and running and have the possibility to go 
from bench to benchside.   
 
Ror2 as a potential biomarker and basis for therapeutic development 
The above results suggest that Ror2 has the potential to be used as a 
possible predictive biomarker or even as a target for targeted therapy.  
Collaborations using Ror2 as the basis for drug discovery are currently in the 
process.  One collaboration initiated with the UNC Center for Integrative Chemical 
Biology and Drug Discovery (CICBDD) will use Ror2’s kinase domains as the basis 
to screen for potential kinase inhibitors.  Utilizing the autophosphorylation properties 
of Ror2, we will use this as the substrate basis for a small molecule inhibitor 
screens.  Potential kinase target hits will be analyzed using Ror2-expressing and 
Ror2-suppressed cells.  Briefly, Ror2-expressing and Ror2-suppressed cells will be 
treated with potential inhibitors and an MTT assay will be used as a functional assay 
to assess cell viability.  To move forward with an inhibitor, we will assess those 
inhibitors that abrogate Ror2-expressing cell viability while Ror2-suppressed cells 
are viable.  To validate potential compounds, immunoprecipitation and 
autophosphorylation assays will be used to analyze Ror2 phosphorylation status 
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changes in response to drug treatment, while xenograft models will be used to 
analyze if the inhibitor causes stabilization or reduction of RCC tumors.  
Within the RCC field, few if any validated tumor specific prognostic indicators 
of death or recurrence of metastatic RCC have been recognized.  Additionally, 
predictive biomarkers are needed in the field as clinical decisions about the use of 
adjunct therapies are based on pathological factors such as tumor grade and stage 
specific factors.  Though this information is good for identifying tumors less or more 
likely to recur, it is not ideal for patients who are in intermediate stages for RCC.  As 
Ror2 is associated with the more aggressive form of RCC, it has the potential to be 
used as a biomarker to identify patients more (or less) likely to develop metastatic 
disease.    
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IN CONCLUSION 
In the course of this study, we have succeeded in our goal of identifying and 
characterizing a potential kinase target for RCC.  We show that Ror2 plays an 
important role in RCC tumorigenesis, is associated with the more aggressive form of 
ccRCC and is also tied to the most commonly mutated gene, pVHL, in RCC.  This is 
the first time that Ror2 has been associated with RCC tumor biology and also 
associated with the VHL/HIF pathway.  The discovery of Ror2 in RCC heralds a 
previously untapped field within the RCC world and has also linked a 
developmentally regulated gene found in RCC to other cancer fields.   
The identification of Ror2 links RCC to a new potential biological avenue 
tightening the bond between RCC and the ECM.  We show that Ror2 plays an 
important role at the ECM and our data suggests that Ror2 can also be linked to the 
epithelial to mesenchymal transition (EMT), an important feature of cancer 
metastasis.  The discovery of Ror2 also opens up the RCC field to an avenue of Wnt 
signaling relevant to RCC that has not been previously uncovered.  Moreover, Ror2 
has a novel pathogenic HIF activation pathway not previously uncovered in other 
pathogenesis.  Though this regulation by HIF is atypical, there has been evidence 
within the literature showing HIF dependent genes that were not drastically induced 
under physiological hypoxia.  An example of this is endosialin/TEM1, which was 
suggested to be regulated by the Ets-1 transcription factor in cooperation with HIF-
2α (39).  Thus, the results we have discovered may help to further explain previously 
unresolved mechanisms for certain identified genes. 
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Additionally, Ror2 has been recognized as having a key role in several cancer 
etiologies, where it is shown to be associated with an invasive phenotype.  The 
discovery of Ror2 in RCC and other cancer types has opened up a new and exciting 
field of study in the cancer world that warrants further exploration.  Not only has the 
identification of Ror2 introduced the potential of a specific target for targeted drug 
therapy, but we have also identified a potential predictive biomarker of cancer that 
has the possibility to be applied to several cancer etiologies.   
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